---
source:
  family: "GUIDANCE"
  instrument: "FDA Guidance"
  title: "The Content of Investigational Device Exemption (IDE) and Premarket Approval (PMA) Applications for Artificial Pancreas Device Systems:  Guidance for Industry and Food and Drug Administration Staff"
  docket: "FDA-2011-D-0464"
  path: "293_The_Content_of_Investigational_Device_Exemption_IDE_and_Premarket_Approval_PMA_Applications_for_Artificial_Pancreas_Device_Systems_Guidance_for_Industry_and_Foo.pdf"
  pages: 64
  converted: 2026-02-27
  method: pdftotext
---

On June 14, 2023, FDA issued a guidance titled “Content of Premarket Submissions for Device
Software Functions.”1 This final guidance supersedes the Guidance for the Content of Premarket
Submissions for Software Contained in Medical Devices, issued on May 11, 2005. The final
guidance issued on June 14, 2023, provides information regarding the recommended
documentation sponsors should include in premarket submissions for FDA’s evaluation of the
safety and effectiveness of device software functions. In particular, the final guidance includes
information to help determine a device’s Documentation Level (formerly known as Level of
Concern). The purpose of the Documentation Level is to help identify the minimum amount of
information that would support a premarket submission that includes device software functions.
Within the framework of the superseded guidance, Artificial Pancreas Device Systems were
considered a device with a Major Level of Concern. Based on the device’s risk in the context of
the device’s intended use, as discussed in the final guidance “Content of Premarket Submissions
for Device Software Functions,” Artificial Pancreas Device Systems should generally address the
recommendations for an Enhanced Documentation Level. The actual Documentation Level for
your device may vary based on the specifics of your device. For more information about the
Documentation Level and recommended documentation for a premarket submission, sponsors
are encouraged to review the guidance “Content of Premarket Submissions for Device Software
Functions.”

1

Available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-premarketsubmissions-device-software-functions.

Guidance for Industry and Food
and Drug Administration Staff
The Content of Investigational
Device Exemption (IDE) and
Premarket Approval (PMA)
Applications for Artificial
Pancreas Device Systems
Document issued on: November 9, 2012
The draft of this document was issued on December 6, 2011, and the Draft
Guidance for Industry and Food and Drug Administration Staff - The
Content of Investigational Device Exemption (IDE) and Premarket
Approval (PMA) Applications for Low Glucose Suspend (LGS) Device
Systems was issued on June 22, 2011.
For questions regarding this document, contact Stayce Beck, Ph.D., 301-796-6514,
stayce.beck@fda.hhs.gov.
U.S. Department of Health and Human Services
Food and Drug Administration
Center for Devices and Radiological Health

Contains Nonbinding Recommendations

Preface
Public Comment
You may submit written comments and suggestions at any time for Agency consideration to the
Division of Dockets Management, Food and Drug Administration, 5630 Fishers Lane, rm.
1061, (HFA-305), Rockville, MD, 20852. Submit electronic comments to
http://www.regulations.gov. Identify all comments with the docket number 2008-D-0095.
Comments may not be acted upon by the Agency until the document is next revised or updated.

Additional Copies
Additional copies are available from the Internet. You may also send an e-mail request to
dsmica@fda.hhs.gov to receive an electronic copy of the guidance or send a fax request to 301847-8149 to receive a hard copy. Please use the document number. Please use the document
number (1759) to identify the guidance you are requesting.

Contains Nonbinding Recommendations

Table of Contents
I.

INTRODUCTION ........................................................................................................................................1

II.

BACKGROUND.......................................................................................................................................2

A.
B.
C.
D.

OVERVIEW...............................................................................................................................................2
CURRENTLY MARKETED DEVICES THAT CAN BE COMPONENTS OF AN APDS ..........................................3
BASIC DESIGN OF AN APDS ....................................................................................................................4
DIFFERENT APDS TYPES.........................................................................................................................6

III.

SCOPE.......................................................................................................................................................7

IV .

DEVICE DESCRIPTION ........................................................................................................................8

A.
B.

C.
D.
E.

APDS SYSTEM LEVEL DESCRIPTION .......................................................................................................9
GLUCOSE MONITORING FUNCTIONAL COMPONENTS ...............................................................................9
CGM Component ...................................................................................................................................9
BGD Component (if applicable)..........................................................................................................10
APDS CONTROL ALGORITHM & SIGNAL PROCESSING FUNCTIONAL COMPONENT ................................11
INFUSION PUMP FUNCTIONAL COMPONENT ...........................................................................................12
COMMUNICATION PATHWAY FUNCTIONAL COMPONENT .......................................................................13

V.

INDICATIONS FOR USE .....................................................................................................................14

V I.

APDS PERFORMANCE .......................................................................................................................15

1.
2.

A.
SOFTWARE.............................................................................................................................................15
B.
REPORT OF PRIOR INVESTIGATIONS (IF APPLICABLE) .............................................................................16
C.
BIOCOMPATIBILITY ................................................................................................................................16
D.
STERILITY ..............................................................................................................................................16
E.
SHELF LIFE ............................................................................................................................................17
F. ELECTRICAL SAFETY .................................................................................................................................18
G.
MAGNETIC RESONANCE (MR) IMAGING SAFETY ...................................................................................18
H.
QUALITY OF RESULTS FROM DIAGNOSTIC DEVICES USED DURING THE CLINICAL STUDY .....................19
I. HUMAN FACTORS ......................................................................................................................................19
J. GLUCOSE MONITORING FUNCTIONAL COMPONENT ...................................................................................22
1. CGM Component .................................................................................................................................22
2. BGD Component..................................................................................................................................23
K.
APDS CONTROL ALGORITHM/SIGNAL PROCESSING FUNCTIONAL COMPONENT ....................................25
L.
INFUSION PUMP FUNCTIONAL COMPONENT ...........................................................................................25
V II. CLINICAL STUDY PROGRESSION ..................................................................................................27
A.
B.
1.
2.
3.

FEASIBILITY STUDIES.............................................................................................................................27
PIVOTAL CLINICAL STUDY .....................................................................................................................30
Patient Population ...............................................................................................................................31
Study Endpoints ...................................................................................................................................33
Statistical Analysis ...............................................................................................................................35

V III.

LABELING .........................................................................................................................................38

IX .

MANUFACTURING..............................................................................................................................39

X.

POST-APPROVAL STUDY..................................................................................................................40

A PPEN D IX A -ID E C O N TEN T FO R A PD S STU D IES ................................................................................41
I.

BA C K G R O U N D .........................................................................................................................................41

Contains Nonbinding Recommendations
II.

D EV IC E D ESC R IPTIO N ......................................................................................................................41

III.

LETTER S O F A U TH O R IZA TIO N ......................................................................................................42

IV .

IN D IC A TIO N FO R U SE .......................................................................................................................42

V.

N O N C LIN IC A L STU D IES/PR IO R IN V ESTIG A TIO N S ..................................................................42

A.
APDS CONTROL ALGORITHM................................................................................................................42
B.
SOFTWARE DOCUMENTATION................................................................................................................44
C.
SUMMARY OF SYSTEM COMMUNICATION ..............................................................................................44
D.
SAFETY MEASURES FOR DOSING ...........................................................................................................44
E.
BIOCOMPATIBILITY TESTING .................................................................................................................45
F. ELECTRICAL SAFETY .................................................................................................................................45
G.
ANIMAL/IN-SILICO TESTING ..................................................................................................................46
H.
HUMAN STUDIES ...................................................................................................................................47
I. HUMAN FACTORS/USABILITY TESTING .....................................................................................................47
J. CATHETER OCCLUSION BENCH TESTING ...................................................................................................48
K.
DOSE ACCURACY BENCH TESTING........................................................................................................48
L.
DIAGNOSTIC DEVICES TO BE USED DURING THE CLINICAL STUDY........................................................49
M.
DRUGS USED DURING THE STUDY .........................................................................................................50
V I.

BIBLIO G R A PH Y ...................................................................................................................................50

V II. C LIN IC A L STU D Y ................................................................................................................................50
A.
PURPOSE/OBJECTIVE(S).........................................................................................................................50
B.
STUDY DESIGN ......................................................................................................................................50
C.
SAMPLE SIZE AND INVESTIGATIONAL SITES ...........................................................................................50
D.
STUDY DURATION .................................................................................................................................51
E.
INCLUSION CRITERIA .............................................................................................................................51
F. EXCLUSION CRITERIA ................................................................................................................................51
G.
STUDY TIMELINE ...................................................................................................................................51
H.
SAFETY MONITORING/RISK ANALYSIS...................................................................................................51
I. STOPPING RULES .......................................................................................................................................53
J. ENDPOINTS ................................................................................................................................................53
K.
SUCCESS CRITERIA/GOAL......................................................................................................................53
L.
STATISTICAL ANALYSIS PLAN ................................................................................................................54
V III.

IN FO R M ED C O N SEN T ....................................................................................................................54

IX .

PA TIEN T C A SE R EPO R T FO R M (S).................................................................................................54

X.

IN V ESTIG A TO R A G R EEM EN T FO R M S .........................................................................................54

X I.

M O N ITO R IN G IN FO R M A TIO N ........................................................................................................55

X II. IN STITU TIO N A L R EV IEW BO A R D (IR B)IN FO R M A TIO N ........................................................55
X III.

LA BELIN G .........................................................................................................................................56

X IV .

A N TIC IPA TED C H A N G ES..............................................................................................................57

X V . M A N U FA C TU R IN G ..............................................................................................................................57
A PPEN D IX B:G LO SSA R Y ..............................................................................................................................58

Contains Nonbinding Recommendations

Guidance for Industry and
Food and Drug Administration Staff
The Content of Investigational Device
Exemption (IDE) and Premarket
Applications for Artificial Pancreas Device
Systems
This guidance represents the Food and Drug Administration's (FDA's) current thinking
on this topic. It does not create or confer any rights for or on any person and does not
operate to bind FDA or the public. You can use an alternative approach if the approach
satisfies the requirements of the applicable statutes and regulations. If you want to discuss
an alternative approach, contact the FDA staff responsible for implementing this
guidance. If you cannot identify the appropriate FDA staff, call the appropriate number
listed on the title page of this guidance.

I.

Introduction

This guidance is intended to provide recommendations to Sponsors1 planning to develop and
submit an Investigational Device Exemption (IDE) or premarket approval (PMA) application
for an Artificial Pancreas Device System (APDS) for single patient use in the home
environment. For the purposes of this document, the APDS refers to low glucose suspend
systems, as well as closed loop control systems. FDA recognizes the need for guidance on the
least burdensome means of development for these innovative device systems. Due to the
evolving nature of these device systems, it is expected that they will develop incrementally.
The recommendations contained in this guidance are intended to provide adequate guidance
and instruction to facilitate the development and marketing of the APDS while, at the same
time, allowing sufficient flexibility to accommodate the different approaches that Sponsors
may wish to take.
This guidance discusses the development and evaluation of APDSs. We describe both
nonclinical and clinical approaches to establishing the safety and effectiveness of an APDS,
and suggest areas where there is flexibility in the pathway to market for these devices.
Specifically, Section VII and Appendix A of this guidance provide detailed information to
1

The term Sponsor is used throughout the submission to indicate both investigators planning research studies
and manufacturers wishing to market the device.
1

Contains Nonbinding Recommendations
assist Sponsors in assembling information to support an IDE submission, while Sections IV –
VI set out the criteria FDA will use in evaluating an APDSs for premarket approval (PMA).
FDA's guidance documents, including this guidance, do not establish legally enforceable
responsibilities. Instead, guidance documents describe the Agency's current thinking on a
topic and should be viewed only as recommendations, unless specific regulatory or statutory
requirements are cited. The use of the word should in Agency guidance means that
something is suggested or recommended, but not required.

II. Background
A . Overview
This guidance lays out many of the possible options for the design, testing and marketing
of an APDS, but it is by no means all-inclusive. We believe the approach in this
document is consistent with the least burdensome principle, and provides maximum
flexibility while assuring that testing is adequate to support marketing approval. In
particular, the guidance:
·
·
·
·

Provides an approach to allow Sponsors to proceed to outpatient studies as
quickly as possible.
Provides maximum flexibility in determining appropriate size and duration of
clinical studies.
Discusses several potential study endpoints that can be utilized to show safety and
effectiveness.
Describes approaches to leveraging existing data about the safety and
effectiveness of the devices already on the market collected from studies done
within and outside of the US, which minimizes the need for preclinical data.

This guidance document provides flexibility in several respects:
Use of Continuous Glucose Monitor Data in the Evaluation of APDSs. We have placed
the primary focus for glucose measurement on a Continuous Glucose Monitor (CGM).
Because patients currently need to periodically calibrate their CGM using a blood glucose
measurement from a blood glucose device (BGD), we have kept the BGD as part of the
APDS, but not the primary focus. We recognize that, over time, improved CGM
performance may obviate the need for periodic blood glucose checks with a BGD, we
have built in the flexibility to eventually allow for the approval of APDS that do not use a
BGD.
Flexibility with respect to Endpoints. We have also introduced a number of suggested
examples of primary endpoints that can be used to measure the safety and effectiveness of
an APDS and support a successful PMA. In addition to these endpoints, we believe that
there may be alternative acceptable primary endpoints. We encourage Sponsors to
discuss their choice of primary endpoint and study design with us.
2

Contains Nonbinding Recommendations

Flexibility with respect to Indication. We give examples of indication statements that we
believe will be the most likely indications for early APDSs and those that would be
supported by the endpoints we suggest, but do not foreclose the possibility of other
indication statements that can be appropriately supported.
Reasonable Study Progression allowing for Quick Outpatient Use. We have set out a
clinical study progression that will move the APDS to outpatient use as quickly as
possible. Each step in the study progression is designed to test specific aspects of the
APDS functionality and performance. The guidance describes how Sponsors who believe
they already have sufficient, valid scientific evidence that fulfills the purpose of a
particular study phase and that justifies moving to the next study phase may do so, using
clinical and non-clinical evidence, and evidence that was obtained from studies
performed outside the US.
Flexibility with respect to Study Size and Duration. We have built in maximum
flexibility regarding the size and duration of each study phase, while also aiming to take
the least burdensome approach. We recognize that study size and duration is dependent
on the design and features of the APDS and its proposed indication. We recognize that
each APDS will likely have unique features that affect study design. In addition, because
some APDSs may be composed of parts that have already been approved or cleared by
FDA, we encourage Sponsors to leverage what we already know about the safety and
effectiveness of the individual components to streamline the clinical testing of such a
system.
We believe the recommendations contained in this guidance will afford Sponsors the
flexibility they need to design innovative, safe and effective systems to treat diabetes
mellitus (DM). We would like to emphasize, that if you believe an alternative, less
burdensome approach to investigating APDSs and developing premarket applications for
these devices can satisfy regulatory requirements for investigation and approval of
APDSs, we encourage you to discuss that approach with the FDA.

B. Currently Marketed Devices that can be components
of an APDS
Today, patients with DM utilize a variety of devices to monitor and manage their blood
glucose levels, including:
·

Hand-held portable BGDs which have been cleared by FDA for home-use, allow
patients to determine their blood glucose levels using blood from a finger stick.
Patients use BGDs multiple times a day to help make decisions regarding insulin
administration and diabetes management around meals, exercise, and other
activities of daily living.

3

Contains Nonbinding Recommendations
·

Some patients also use continuous subcutaneous insulin infusion (CSII) via an
insulin pump to manage their disease.

·

Some patients use a CGM system, which uses a sensor inserted into the
subcutaneous tissue and continuously (meaning, at a consistent interval) measures
the concentration of glucose in the interstitial fluid. While CGM devices have not
yet reached a performance level that would make them an adequate substitute for
BGDs, they do allow patients to monitor trends and patterns of glucose levels in
their bodies.

Even with the aid of these devices, maintaining blood glucose concentrations within a
suggested optimal range is a daily struggle for people living with DM and the risk of
hypoglycemia associated with attempts at improved glycemic control remains an everpresent danger.

C . Basic Design of an APDS
APDSs link a CGM to an insulin pump and automatically reduce or increase insulin
infusion based upon specified thresholds of measured interstitial glucose. The APDS
parts are designed to communicate with each other to automate the process of maintaining
blood glucose concentrations at or near a specified target or range and minimize the
incidence and severity of hypoglycemic (dangerously low blood sugar) and
hyperglycemic (dangerously high blood sugar) events.
The illustration below describes the parts of an APDS and depicts how they work
together.

4

Contains Nonbinding Recommendations

(1) Continuous Glucose Monitor (CGM). A CGM provides a steady stream of
information that is intended to reflect the patient’s blood glucose levels. A sensor
placed under the patient's skin (subcutaneously) measures the glucose in the fluid
around the cells (interstitial fluid), which has been found to correlate with blood
glucose levels. A small transmitter sends information to a receiver. A CGM
continuously displays both an estimate of blood glucose levels and their direction and
rate of change of these estimates.
Blood Glucose Device (BGD). Currently, to get the most accurate estimates of
blood glucose possible from a CGM, the patient needs to periodically calibrate the
CGM using a blood glucose measurement from a BGD; therefore, the BGD still
plays a critical role in the proper management of patients with an APDS.
However, over time, we anticipate that improved CGM performance may obviate
the need for periodic blood glucose checks with a BGD.
(2) APDS Control algorithm. An APDS control algorithm is software embedded in
an external processor (controller) that receives information from the CGM and
performs a series of mathematical calculations. Based on these calculations, the
controller sends dosing instructions to the infusion pump.
(3) Infusion pump. Based on the instructions sent by the controller, an infusion
pump adjusts the insulin delivery to the subcutaneous tissue.

5

Contains Nonbinding Recommendations
(4) The Patient. The patient is an important part of the APDS. The concentration of
glucose circulating in the patient’s blood is constantly changing. It is affected by the
patient’s diet, activity level, and how his or her body metabolizes insulin and other
substances.

D . Different APDS Types
Although the fundamental components described above are common to all APDSs,
different device designs, control algorithms, and patient management strategies create the
potential for different APDS types, including:
·

A Threshold Suspend Device System2 may reduce the likelihood or severity of a
hypoglycemic event by suspending or reducing insulin delivery temporarily when
the sensor value reaches or approaches (reactive or predictive, respectively) a
predetermined lower threshold of measured interstitial glucose. When a sensor
value is above (or predicted to remain above) the threshold, the infusion pump
will not take any action based upon CGM readings. Patients using this system still
need to monitor their blood glucose concentration, set appropriate basal rates for
their insulin pump, and give pre-meal bolus insulin to maintain control of their
glucose levels.

·

A Control-to-Range (CTR) system that reduces the likelihood or severity of a
hypoglycemic or hyperglycemic event by adjusting insulin dosing only if a
person's glucose levels reach or approach predetermined higher and lower
thresholds. When a patient's glucose concentration is within the specified range,
the infusion pump will not take any action based upon CGM readings. Patients
using this system still need to monitor their blood glucose concentration, set
appropriate basal rates for their insulin pump and give pre-meal bolus insulin to
maintain control of their glucose levels.

·

A Control-to-Target (CTT) system that sets target glucose levels and tries to
maintain these levels at all times. This system is fully automated and requires no
interaction from the user (except for calibration of the continuous glucose
monitoring system). There are two subtypes of CTT systems currently being
investigated (i.e., insulin-only and bi-hormonal) and a hybrid system option
(patient administration of a pre-meal or partial pre-meal insulin bolus) that can be
used in either of the system types.

CTR and CTT System Subtypes are dependent upon the drug or drugs being
delivered and how each drug affects glucose concentrations. Subtypes may include:
·

2

An insulin-only system that achieves a target glucose level by increasing or
decreasing the amount of insulin infused.

Threshold Suspend Device Systems are sometimes also referred to as Low Glucose Suspend Device Systems.
6

Contains Nonbinding Recommendations
·

A bi-hormonal control system that achieves a target glucose level by using
APDS control algorithm(s) to instruct an infusion pump to deliver two different
hormones — one hormone (insulin) to lower glucose levels and another hormone
(such as glucagon) to increase blood glucose levels. The bi-hormonal system
mimics the glucose-regulating function of a healthy pancreas more closely than an
insulin-only system.

Some investigations for CTR and CTT have explored the use of concomitant
medications. While these medications are not an integral part of the closed-loop system
concurrent administration may be needed for the system to function as intended.

III. Scope
This guidance is focused on the development, investigation, and information to include in
premarket applications (PMAs) and Investigational Device Exemptions (IDEs) for APDSs –
autonomous systems that modulate insulin delivery for a variety of purposes such as: to
temporarily reduce or suspend insulin infusion to minimize hypoglycemia; to maintain blood
glucose concentrations within a prespecified range; or to maintain blood glucose
concentrations at a prespecified target. The guidance provided in this document is intended
for APDSs used outside of a healthcare facility. Although elements of this guidance may be
applicable to APDSs used in a health facility, additional considerations outside the scope of
this guidance may also need to be addressed. This guidance was written to both
accommodate APDSs utilizing current technologies, and permit application of the principles
described in this guidance to newer technologies.
As described in the Background Section above, the wide variety of CGMs, BGDs, insulin
pumps, and APDS control algorithms available allows for a number of different types and
designs of APDSs. We anticipate that some APDSs will utilize already cleared or approved
components. Others may utilize components that have been modified in some way. The
information Sponsors should submit when changes are made to the different components, or
when components are substituted into an already approved APDS, will depend on the effect
the change is anticipated to have on system performance. For example, additional clinical
studies may not be needed if a Sponsor is able to demonstrate that a newly introduced
component is similar to the previously approved version, e.g., its accuracy, susceptibility to
interferences, human factors, etc.
For purposes of this document, FDA defines an APDS as including the following
components:
· Glucose Monitoring Devices – a CGM and BGD used for calibrating the CGM
(where applicable) and checking sensor performance as needed plus associated
reagents/test strips;
· APDS Control algorithm;
· Infusion pump - Fluid infusion set for the complete fluid pathway from, and
including, the drug reservoir or fluid source container (e.g., bag, cassette, vial,

7

Contains Nonbinding Recommendations

·

syringe), infusion set, extension sets, filters and valves, clamps, up to and including
the patient connection;
Components and accessories (e.g., power cord, wireless controller); and

The primary product codes for an APDS are:
· OZO: Artificial Pancreas Device System, threshold suspend
· OZP: Artificial Pancreas Device System, single hormonal control
· OZQ: Artificial Pancreas Device System, bihormonal control
All three of these systems are regulated as class III device systems.
This guidance applies only to APDSs that use insulin products that have been approved by
the FDA for delivery via an infusion pump, and that are used in accordance with their FDAapproved labeling. This guidance does not address data requirements for a drug labeling
modification such as approval of a new drug formulation or drug delivery method. Also, this
guidance does not apply to APDSs that utilize synthetic or artificial cells, tissues or organs
nor does it address issues that are unique to combination products3.
Although elements of this guidance may be applicable to these circumstances, additional
considerations outside the scope of this guidance may also need to be addressed.

IV . Device Description
APDSs currently consist of a number of device components that communicate to form a
complete system. The unique qualities of these systems stem from the interaction of the
various device components to achieve the system’s intended use. To unify the device
description for all types of APDSs, Sponsors should describe: (i) the device system as a
whole, and (ii) each of the functional components within the device system. FDA
recommends Sponsors provide the following information as part of the APDS device
description:

3

21 CFR 3.2(e): Combination product includes: (1) a product comprised of two or more regulated components,
i.e., drug/device, biologic/device, drug/biologic, or drug/device/biologic, that is physically, chemically, or
otherwise combined or mixed and produced as a single entity: (2) two or more separate products packaged
together in a single package or as a unit and comprised of drug and device products, device and biological
products, or biological and drug products; (3) a drug, device, or biological product packaged separately that
according to its investigational plan or proposed labeling is intended for use only with an approved individually
specified drug, device, or biological product where both are required to achieve the intended use, indication, or
effect and where upon approval of the proposed product the labeling of the approved product would need to be
changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant
change in dose; or (4) any investigational drug, device, or biological product packaged separately that according
to its proposed labeling is for use only with another individually specified investigational drug, device, or
biological product where both are required to achieve the intended use, indication, or effect.

8

Contains Nonbinding Recommendations

A . APDS System Level Description
The Sponsor should provide the following descriptive information regarding the device
system:
·

A clear statement of the intended use and indications for use (see Section V).

·

A picture or schematic of the entire system, and how the components interface.

·

A listing of all the device functional components and accessories that are part of
the system (including model numbers).

·

Because the system is intended to be used outside of a healthcare facility, a
description should be provided on features of the system designed to address
issues such as mobility, various environmental conditions (e.g., water exposure,
altitude, electromagnetic interference), and ruggedness.

·

Because the system is intended for lay use, a description should include features
of the system designed to address how the device will provide assurances for safe
and effective use by the lay populations, which often have limited or no clinical
background and may have functional limitations.

·

Detailed description of the technological features of the system (e.g., alarms, etc.).

·

Detailed description of the training for all persons involved with an APDS. See
Appendix A, V.I, below for a discussion of Human Factors and other training
considerations.

For each of the device functional components, the descriptive information identified in
the following sections should be provided.

B. Glucose Monitoring Functional Components
Sponsors should provide the following information for the functional components of the
APDS that serve to monitor glucose levels in the patient.

CGM Component

1.
·

The regulatory status of the CGM component.
o If a modified version of an approved CGM is used, the Sponsor should
provide a comprehensive list and description of the modifications to the
CGM, and provide the rationale for the change(s). This might include
instructions for use, such as the required run-in period or calibration, or
changes to the CGM algorithm or physical structure.
o If it is an already approved CGM, the Sponsors should provide:

9

Contains Nonbinding Recommendations
§

§

The name of the CGM and the FDA document number under which it
was approved (noting the appropriate Supplement number and the date
of the Supplement).
If the Sponsor wishes to rely on information previously submitted by a
different Sponsor, a letter of authorization granting access to the
information.

o If the CGM is not already approved or if the CGM algorithm has been
modified and not previously reviewed by FDA, the Sponsor should also
provide a description of the signal processing starting from the raw CGM
signal to the reported CGM value. This should describe the method (e.g.,
signal averaging) of calculating the reportable CGM value, the frequency
of reporting the CGM value, and the signal processing that is performed
for the calibration method.
·

Description of the function(s) the CGM performs in the APDS.

·

Description of the methodology employed for glucose measurement (e.g.,
electrochemical measurement).

·

Description of the sample matrix analyzed (e.g., interstitial fluid).

·

Description of the anatomical site(s) into which the sensor is inserted, and the
recommended distance between the CGM and the infusion pump unit.

·

Description of the information provided by the CGM, such as the frequency of
reported glucose values, trending information and alarms.

·

Device description, including a list of all device components and accessories.
As appropriate, this would include sensors, display monitors, devices to aid in
the insertion of the sensor, quality control materials, standards (calibrators),
and software.

2. BGD Component (if applicable)4
· The regulatory status of the BGD.
·

If modified, a comprehensive list and description of all modifications and a
rationale for the change(s).

·

Description of the function(s) performed by the BGD.

4

As noted above, currently, to get the most accurate readings possible from a CGM, the patient needs to
periodically calibrate the CGM using a blood glucose measurement from a BGD; therefore, the BGD still plays
a critical role in the proper management of patients with an APDS. However, over time, we anticipate that
improved CGM performance may obviate the need for periodic blood glucose checks with a BGD.
10

Contains Nonbinding Recommendations

·

A list of all BGD functional components and accessories, as appropriate. In
addition to the instrument, reagents and quality control materials, accessories
might include standards (calibrators), data transmitting equipment or software
that processes or stores data or quality control results.

·

A summary description of the measurement method utilized by the BGD (e.g.,
electrochemical, spectrophotometric measurement).

·

A description of the test principle, i.e., all chemical reactions and
concentration of all reagent components.

·

Matrix of blood sample to be analyzed (e.g., fingerstick capillary blood).

C . APDS Control Algorithm & Signal Processing
Functional Component
The description of the APDS control algorithm functional component should include all
computational steps, including CGM signal and changes in the command for insulin
delivery. The APDS control algorithm should also include the following information:
·

Description of how the APDS control algorithm addresses signal dropout and time
periods required for CGM changes; and, if applicable, a description of any
analyses that occur to determine if the CGM value is artifact or real (in addition to
processing performed as part of the CGM algorithm).

·

Description of the APDS control algorithm that adjusts insulin dosing. This
description should be detailed sufficiently to allow the recreation of the APDS
control algorithm. This should include:
o Defining the type of control strategy used (e.g. model predictive control, PID
(proportional integral derivative), etc.)
o Defining the inputs, outputs, and disturbances in a block diagram.
o Defining the parameter name for the APDS control algorithm equation(s),
including any state variables.
o Defining all parameters that cannot be modified (fixed parameters) by the user
and/or healthcare provider and their corresponding parameter value.
o Defining all parameters that are adjustable by the user and/or healthcare
provider, including:
§ Defining the parameter value range and the smallest increment that the
parameter can be adjusted, and
§ Identifying the user that can adjust the parameter (i.e., patient or healthcare
provider) and describe how the device secures these parameter values that
are adjustable only by the specified user.

11

Contains Nonbinding Recommendations
·

Summary of the minimum and maximum insulin delivery dose recommendation
and velocity limit of the APDS control algorithm.

·

If applicable, a description of any safety check that the system performs to ensure
the insulin pump has delivered the appropriate dose.

·

Description of the signal processing from the dosing recommendation to the raw
signal current command.

·

Summary of the verification activities to show the APDS control algorithm has
been properly coded into the software.

D . Infusion Pump Functional Component
The description of the infusion pump functional component should include the following
information:
·

If the infusion pump is labeled for use with a specific drug, the labeling should be
consistent with the approved indications and route of administration. To facilitate
FDA’s review, the FDA approved labeling for that device or drug should be
provided.

·

A detailed description (including, where appropriate, assembly drawings,
schematics, and/or specification control documents) of the pump and its
functional components, and accessories including:
o The infusion delivery mechanism;
o The bolus mechanism;
o The drug reservoir;
o Pump tubing and connectors (built-in or external to the pump);
o A user-interface, consisting of the programming unit, display unit, audio and
tactile notification units;
o Power supply or pump battery and circuitry to charge the battery;
o A communication interface, including network components and interfaces to
other devices and systems, and
o Refill frequency. (this should be consistent with the approved labeling for the
drug).

·

The principle of operation of the infusion pump (i.e., the scientific principles
behind how the device achieves its intended use).

·

Identification and description of particular infusion sets or cassettes that will be
provided or recommended for use with the APDS, if any.

·

The user interface components of the pump, including keypads, control menus,
data entry screens, displays, indicator lights, alarms, auditory and tactile feedback,
12

Contains Nonbinding Recommendations
infusion sets, cassettes, free-flow prevention mechanisms, tubing, latches, doors
or other components of the physical pump that may be manipulated.
·

A detailed design description of the software utilized by the device, if any,
including all key elements.5

·

The specifications for the infusion device (e.g. flow rate accuracy specifications
for bolus and basal deliveries, time to deliver bolus, etc.).

E. Communication Pathway Functional Component
The description of the Communication Pathway functional component should describe
the passage of information between the functional components, including a description of
the hardware and software that allows the passage of information. The description should
include:
·

Communication pathway. Sponsors should describe all of the ways each
functional component communicates to other functional components within the
system. The Sponsor should identify the flow of communication (e.g.,
unidirectional or bidirectional) between the functional components and identify
the information that is passed. This description should also include information on
the rates of data exchange and procedures for lost connections (i.e. what is the
default signal to the pump?), as well as procedures for taking into account periods
required for an exchange of an old CGM with a new one, including equilibration
periods.

·

Communication hardware. Sponsors should describe how the information is
passed between each functional component and describe the hardware necessary
to communicate this information.

·

If the system incorporates or is intended to incorporate radio-frequency (RF)
wireless technology (e.g., IEEE 802.11, Bluetooth, Zigbee), the description should
include information about the specific RF wireless technology and characteristics,
its use and functions (e.g., remote monitoring or control, software updates), the
data to be transmitted including any alarms by wireless transmission, quality of
service (QoS) needed, wireless security protocols, and any limitations or
restrictions relating to coexistence with other RF wireless technology or
electromagnetic interference (EMI).

·

If the device is capable of being remotely controlled or monitored from a distance,
this capability should be identified with a description of the measures
incorporated to assure safety.

6

See Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices
(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm089543.htm) for
more information.
13

Contains Nonbinding Recommendations

·

Reliable communication between the various device components of the APDS is
essential to ensure the correct information is passed to each device component.
The Sponsor should describe how the system ensures communication with only
the devices approved with the system.

V . Indications for Use
The indications for use statement is “a general description of the disease or condition the
device will diagnose, treat, prevent, cure, or mitigate, including a description of the patient
population for which the device is intended.”6 The indications for use statement of different
APDSs may differ depending on the device design and intended patient population.
Indications should be proposed based upon the design of the APDS control algorithm,
clinical study design, and the intended patient population, although we recognize that APDS
currently in the research and development phase may not have a final indication until they
have been studied in depth.
The following statements are provided as examples of appropriate wording for likely
indications for use:
·

The APDS is intended for patients with type 1 diabetes for the subcutaneous infusion
of insulin and the continuous measurement of interstitial glucose to aid in the
management of their disease. The APDS automatically adjusts insulin delivery in
response to CGM values that have exceeded or are predicted to exceed the bounds of
a prespecified blood glucose range. The APDS is intended to assist the patient in
managing their disease.

·

The APDS is intended for patients with type 1 diabetes mellitus for the subcutaneous
infusion of insulin and the continuous measurement of interstitial glucose to aid in the
management of their disease. The APDS automatically adjusts insulin delivery in
response to CGM values to maintain a prespecified target glucose concentration. The
APDS is intended to assist the patient in managing their disease.

FDA recognizes, however, that alternative indication statements may be appropriate
depending on the populations and endpoints studied. Sponsors who plan to submit a PMA
for an APDS that is specifically intended to improve glycemic control or reduce
hypoglycemia should be sure to measure those features as endpoints in the pivotal clinical
study designed to support the PMA submission. Sponsors seeking to support different
indications for use should discuss appropriate study design and labeling statements with
FDA. Under 21 CFR 814.20(b)(3)(vi), the PMA must include valid scientific evidence to
support the labeled use.

6 See 21 CFR 814.20(b)(3)(i).
14

Contains Nonbinding Recommendations

V I. APDS Performance
The APDS performance should be described in both IDE and PMA submissions. The
information needed for an IDE is discussed in Appendix A. FDA recommends the
following information and performance characteristics be provided in the PMA:

A . Software
Software documentation is an important aspect of device validation. The Sponsor should
provide complete software documentation in the PMA. Some useful guidance documents
for software considerations are provided below.
·

FDA considers the APDS and all of the components of the system to be a “Major”
level of concern for the purposes of software review. The information Sponsors
should provide in their submissions regarding software has been delineated in the
Guidance for the Content of Premarket Submissions for Software Contained in
Medical Devices
(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDo
cuments/ucm089543.htm). .

·

If the device includes off-the-shelf software, additional information should be
provided as recommended in the Guidance for Industry, FDA Reviewers and
Compliance on Off-the-Shelf Software Use in Medical Devices
(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDo
cuments/ucm073778.htm).

·

Cyber Security - FDA recommends that the concept of information security be
addressed when medical devices can store, access, and/or transfer information.
Information security is the process of preventing the modification, misuse, and
denial of use or the unauthorized use of that information. Specific concepts are
confidentiality, integrity, availability and accountability (CIAA) :
o Confidentiality assures that no unauthorized users have access to the
information.
o Integrity is the assurance that the information is correct - that is, it has not
been improperly modified.
o Availability suggests that the information will be available when needed.
o Accountability is the application of identification and authentication to assure
that the prescribed access process is being done by an authorized user.

Communication between device components should be secure and prevent
communication from other devices that are not part of the system. For additional
guidance on cybersecurity, please refer to Guidance for Industry, Cybersecurity for
Networked Medical Devices Containing Off-the-Shelf (OTS) Software
(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocument
s/ucm077812.htm).

15

Contains Nonbinding Recommendations

B. Report of Prior Investigations (if applicable)
Data from prior investigations – both clinical and nonclinical -- should be included as part
of the PMA to the extent applicable. The Report of Prior Investigations should include a
summary of non-clinical information relied upon to address basic device safety,
characterize catastrophic failure modes and risk mitigation approaches, and support an
expectation that the device will function as intended. The PMA must contain a
bibliography of published reports and an identification and discussion of other data and
information relevant to the safety and effectiveness of the APDS. 21 CFR 814.20(b)(6)
and (8).

C . Biocompatibility
Biocompatibility testing of the APDS should be performed on the final, finished,
sterilized device for all device components and accessories. The PMA should include a
complete test report of each biocompatibility test performed. Alternatively, if
biocompatibility information for a test component has been previously evaluated and
found acceptable by FDA (such as during separate premarket review of the component),
the Sponsor may provide a summary of the testing procedures and study. In this case, the
Sponsor should reference the FDA document number. See Appendix A, Section V.E for a
discussion of the biocompatibility testing needed for IDE submissions.
Generally, biocompatibility tests for a PMA device should be performed in a manner
appropriate for the duration and level of contact the patient is likely to have with the
device. We recommend that Sponsors consider the components of an APDS to have
prolonged duration of contact with the patient because of the way the device and its
accessories will be used.
For additional information and detailed instructions on biocompatibility testing, we
recommend following the FDA blue book memo entitled, Use of International Standard
ISO 10993, ‘Biological Evaluation of Medical Devices Part 1: Evaluation and Testing’
(.http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocumen
ts/ucm080735.htm).

D . Sterility
Each of the device components used in the APDS may call for different types of
processing or reprocessing based on their intended use. The intended use will determine
whether a device must be sterile, such as an implant that will be contacting normally
sterile locations within the body, or whether a lesser degree of microbicidal processing,
such as a reusable component that is intended to contact only intact skin is sufficient.
For sterile device components, use of FDA recognized consensus standards for
conducting process development and validation testing is recommended. A searchable
list of these standards is available at
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm.
16

Contains Nonbinding Recommendations

Products labeled “sterile” should be processed using methods that have been
comprehensively validated by the Sponsor to provide a sterility assurance level (SAL) of
10-6.
The product labeling should prominently indicate whether each component is supplied in
a sterile or non-sterile state. For device components that are not sterile, we recommend
that the Sponsor provide a scientifically valid rationale for why sterilization is
unnecessary.
APDSs and accessories intended for prolonged use should include instructions in the
labeling for proper cleaning and disinfecting, as appropriate, between uses. Also, where
appropriate, “use life” information (e.g., how long the device should be used before
replacing) should be provided in the labeling, with supporting information. This may
include information such as the number of times the device can be reused, or guidance as
to how users can make that determination (e.g., inspecting for wear and tear). APDSs are
intended to be used in the home environment. The Sponsor should indicate cleaning
agents/products in the labeling that are readily available to the average home user along
with validated instructions for cleaning the device in a manner that is consistent with the
FDA guidance for labeling reusable devices.7 In addition, reference to relevant Technical
Information Reports (TIR) developed by the Association for the Advancement of Medical
Instrumentation (AAMI) when developing labeling instructions for reusable medical
devices is recommended.8,9
If sterility or the cleaning and disinfection of specific system components has been
previously evaluated and found acceptable by FDA (such as during the premarket review
of the component), the Sponsor should provide a summary of testing procedures, the
study results, and the FDA document number where additional information can be found.
This approach may be acceptable if the way in which the component is used and the way
it is packaged has not changed from the time of the original clearance/approval. The
Sponsor should provide a justification explaining why the change does not affect sterility.

E. Shelf Life
The shelf life of the APDS, including accessories, should be supported with appropriate
data, including both performance-based testing and package integrity, when applicable.
Performance
If the particular system contains sterile components, materials or reagents that could
degrade over time, a shelf life should be included on the packaging. Additionally,
7

See
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm252999.htm.
8
AAMI TIR 12:2010, Designing, testing and labeling reusable medical devices for reprocessing in health care
facilities: A guide for medical device manufacturer
9
AAMI TIR 30:2003, A compendium of processes, materials, test methods, and acceptance criteria for cleaning
reusable medical devices
17

Contains Nonbinding Recommendations
performance data should be generated after an appropriate number of complete “use
cycles” which should include cleaning or disinfection per the labeling.
The Sponsor should also provide data demonstrating that the APDS can maintain the
performance specifications throughout the system’s shelf life. If accelerated test methods
are utilized, the Sponsor should demonstrate that the test methods accurately simulate
real-time conditions for the device.
Package Integrity
The Sponsor should ensure that device package design and construction are validated to
protect the device components from alteration or damage during shipping, handling, and
transportation. The packaging should also be validated to support the labeled shelf life
(e.g., 1 year, 3 years). The validation process should be designed to assure that packaging
will maintain its integrity (no breaches of the sterile barrier system) after being subjected
to the rigors of the real world (i.e. less-than-ideal shipping and handling conditions), as
well as stability testing (i.e., aging). This typically calls for two validation test pathways:
simulated shipping of packaged product (or accurate surrogate of product) followed by
package integrity testing, and simulated (accelerated) aging followed by seal strength
testing. We recommend that confirmatory, real-time package shelf life testing be
submitted as part of the PMA. We also recommend that Sponsors use recognized
consensus standards for conducting these various simulations and validation tests.10,1112
If the shelf life (or expiration dating) of a system component has been previously
evaluated and found acceptable by FDA (such as during the premarket review of the
component), the Sponsor may submit a summary of testing procedures and study results
along with the FDA document number where additional information can be found. This
approach is only acceptable if the way in which the component is used and the way it is
packaged has not changed from the time of the original approval. The Sponsor should
provide a justification of why the change does not affect package integrity.

F. Electrical Safety
A complete test report should be provided in the PMA submission describing the
electrical safety testing used to support approval of the APDS. Details of the electrical
safety can be found in Appendix A Section V.F.

G .Magnetic Resonance (MR) Imaging Safety
Sponsors should clearly identify on the APDS and its label whether it is MR Safe, MR
conditional, or MR unsafe. For information regarding Magnetic Resonance (MR) Imaging
safety testing and labeling, please see FDA’s guidance document, Establishing Safety and
10

AAMI / ANSI/ ISO 11607-1:2006, Packaging for terminally sterilized devices – Part 1: Requirements for
materials, sterile barrier systems and packaging systems.
11
AAMI / ANSI/ ISO 11607-2:2006, Packaging for terminally sterilized devices – Part 2: Validation
requirements for forming, sealing, and assembly processes.
12
ASTM D4169-09, Standard Practice for Performing Testing of Shipping Containers and Systems.
18

Contains Nonbinding Recommendations
Compatibility of Passive Implants in the Magnetic Resonance (MR) Environment
(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocument
s/ucm107705.htm). While the subject of the referenced guidance is passive implants, the
information contained in it is also relevant for active devices like APDS.

H .Quality of Results from Diagnostic Devices Used
During the Clinical Study
Clinical studies often include in vitro diagnostic devices (IVDs) that provide information
used as an endpoint of the study, e.g., Hemoglobin A1c (HbA1c), urine or blood ketone
results, or blood glucose results from a device other than the BGD used to calibrate the
CGM component of the APDS. Therefore, evidence is needed to support the quality of
those results. Sponsors should provide the following information:
·
·

·
·
·
·
·

The name of the device, and the associated reagent(s);
An indication of the regulatory status of the device:
o If it has already been granted marketing approval or clearance, Sponsors
should provide the FDA document number where additional information can
be obtained, if known; or
o If the device has not been granted marketing approval or clearance, Sponsors
should provide data supporting the accuracy and reliability of the device..
Any qualifying certifications of the reagent or test system, e.g., National
Glycohemoglobin Standardization Program certification;
The name and concentration levels of the Quality Control (QC) materials run to
confirm proper performance of the device during the study;
The frequency or points in time when QC material(s) were analyzed;
How it was determined that the devices were functioning properly, e.g., any
functional checks performed or criteria applied to QC material results; and
A statement certifying that a copy of the labeling was provided to each user who is
operating a device at home, or that it was available to staff who operated a device
in an in-patient setting.

I. Human Factors
The device user interface plays a critical role in the performance of the APDS and should
be considered integral to the overall performance of these systems.
Reports of device-related incidents and recalls for diabetes devices have shown that
patterns of use errors resulting from deficiencies in the design of the user interface have
led to patient harm. Human factors testing can help identify and mitigate these
deficiencies. For this reason, FDA recommends that PMAs include comprehensive
application of human factors in the design and evaluation of the user interface
components of the entire APDS.

19

Contains Nonbinding Recommendations
The term user interface denotes all components of the device system with which the user
interacts; for example:
·
·
·
·

Control mechanisms (e.g., key pads, touch screens, slide controls).
Feedback mechanisms (e.g., auditory alarms, visual alarms, status indicators, and
other messages to users).
Graphical user interface, including representations of responses to user actions
(including visual feedback related to changes in device operation or status).
Labeling (including directions for use, user manuals, quick-start guides, package
inserts, information on packaging, etc.).

Hazards associated with use of functional components of the APDS are unique in that
they exist even if a device operates within its specifications. These hazards often do not
involve failures due to faulty mechanical, electrical or software components that are
previously known or reasonably anticipated but rather, arise specifically from interaction
with a human operator. Analyses of use-related hazards should consider the following:
·

The safety of interactions between the user and all parts of the user interface
components of the system:
o Adequacy and convenience of the arrangement of user interface components
for users’ physical interactions with the device.
o Potential errors associated with atypical user actions or techniques.
o Legibility of visual information, including device labels and displays.
o Audibility and distinctiveness of auditory information, including different
alarm tones and logic of alarm activation.

·

Potential use errors or difficulties associated with:
o Each possible setting or input available to operators.
o Input, selection or modification of critical treatment parameters.
o Non-standard or unusual parameter settings or default values.
o Non-standard, unfamiliar or ambiguous conventions or abbreviations.
o Non-standard, ambiguous, or inadequate alarm condition or informational
messages.
o Improper storage conditions (e.g., test strip/reagent storage temperature and
humidity, etc.).
o The user’s inability to understand the indications for use of the device and
limitations of the device.

·

Potential errors associated with use of the CGM component, including:
o Incorrect data entry during CGM calibration.
o Improper timing of CGM calibration (e.g., when conditions are not optimal).
o Failure to calibrate the CGM at the recommended frequency.
o Failure to discontinue CGM use at the end of the sensor wear period when
CGM results may be compromised (e.g., when there is no hard stop on CGM
results generation).
20

Contains Nonbinding Recommendations
o Improper anatomical placement of CGM.
o Use of an expired sensor.
o Use of the CGM under inappropriate conditions.
·

Potential errors associated with use of the BGD used to calibrate the CGM
component, including:
o Improper fingerstick sampling technique (e.g., "milking" the finger).
o Failure to take a fingerstick sample to confirm questionable CGM readings
(e.g., that do not correspond with user’s clinical symptoms or user’s
expectations of what glucose should be at that time).
o Inadequate volume of blood sample collected.
o Failure to follow recommended quality control procedures.
o Improperly performing quality control procedures.
o Use of expired reagents or test strips.
o Improper storage of BGD reagents or test strips
§ Note: This error is extremely important for Sponsors to address. Improper
test strip storage (e.g., in car glove compartments) is identified as the most
common source of error by manufacturers when consumers report an
improperly functioning BGD.
o Improper handling of reagents or test strips, such as leaving the reagent bottle
cap off for longer than is recommended.
o Inadequate cleaning or maintenance of the BGD.
o Patients using a BGD to calibrate the CGM during conditions which are
contrary to use of the BGD. For example, measurements from many BGDs
are affected by conditions such as ketoacidosis, hypoglycemia or ingestion of
large doses of vitamin C.

The APDS development process should include human factors/usability testing to ensure
that the device system will be safe and effective in the hands of the intended users. This
testing should be conducted with people who are representative of the intended users and
under conditions that are comparable to actual conditions of use. The intended users
should be defined precisely but they might include health care providers, patients, and lay
caregivers (e.g., elderly spouses or parents of children), and the users’ ages and functional
capabilities could span a wide range. The conditions of use should include provision of
labeling, such as instructions for use, and training that is comparable to the training that
actual users will receive. The testing should assess not only the user interface components
of the devices in the system, but also the adequacy of the labeling and training to support
users to use the system safely and effectively.13
13

FDA has distributed draft guidance on the use of human factors in optimizing medical device design, Draft
Guidance for Industry and Food and Drug Administration Staff – Applying Human Factors and Usability
Engineering to Optimize Medical Device Design
(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm259748.htm).
Although the recommendations contained in this guidance are not in effect at the time of publication of this
guidance, general information contained in the guidance about human factors considerations in medical device
design is relevant to an understanding of this topic.

21

Contains Nonbinding Recommendations

J. Glucose Monitoring Functional Component
1.
CGM Component
Sponsors should provide appropriate information regarding the safety and
effectiveness of the CGM functional component when used as part of an APDS.
Sponsors may find it helpful to review the FDA-recognized Clinical Laboratory
Standards Institute (CLSI) POCT 05-A guideline14 and applicable FDA guidance
documents.
Sponsors should provide protocols and test reports for the following performance
characteristics established during the pivotal CGM trial:
·

·

·

·

·
·

14

Accuracy of CGM results. Sponsors should characterize accuracy by
summarizing the point-to-point agreement between blood glucose reference
readings and paired CGM results. Sponsors should present the total and
cumulative percentage (and numbers) of CGM values presented as various
differences from the paired blood glucose reference result (e.g., within 10, 20,
30, 40 or >40 mg/dL). FDA recommends that blood glucose reference values
be stratified according to glucose concentration (as determined by the blood
glucose reference values) in various glucose concentration bins (e.g., <40, 4150, 51-60, 61-70, 71-80, 81-120, 121-180, 180-250, 250-325, and 326-400
mg/dL).
Bias across the reportable range of the CGM. Sponsors should calculate bias
at various glucose concentrations (according to the blood glucose reference
values) of 60, 80, 120, 180, 250, 325, and 400 mg/dL and should include 95%
confidence intervals.
Threshold alarm performance (Detection rates and false alarm rates). In
addition to point-to-point alarm detection rates, detection rates should also be
characterized according to whether the CGM detected the hypoglycemic and
hyperglycemic event within 15 and 30 minutes of the event. False alarms
should be similarly characterized in a point-to-point analysis and also in an
analysis which does not consider an alarm a false alarm if the event actually
occurred within plus or minus 15 and 30 minutes of the alarm.
Prediction alarm performance. Performance of representative prediction
alarms that are utilized in the APDS should be summarized. Sponsors should
characterize detection rates according to whether the CGM detected the
predicted hypoglycemic and hyperglycemic glucose level within the horizon
setting(s). A similar analysis should be performed for the false alarm rate.
Imprecision observed when sensors are inserted into the same anatomical site
and when sensors are inserted into different anatomical sites.
Analytical specificity, including:
o Cross-reactivity with molecular compounds similar to glucose.

CLSI POCT 05-A, Performance Metrics for Continuous Interstitial Glucose Monitoring.
22

Contains Nonbinding Recommendations
o Interference (both endogenous and exogenous compounds/conditions, as
well as both prescription and over-the-counter medications).
o Environmental interference (e.g., from temperature or water exposure,
such as bathing or swimming, etc.).
o Interferences due to medical condition of the patient such as ketoacidosis
and fever.
Study protocols should minimally include, as applicable: number of patients, number
of samples tested, number of replicates of each sample tested, number of devices
tested, matrix and concentration of the sample tested, how CGM and blood glucose
reference readings were paired and the statistical analysis used.
Sponsors should summarize important user functions as characterized during the
CGM pivotal clinical trial, including:
·
·

Length of sensor wear period. Sponsors should present the distribution of the
number of hours that sensors remained functional.
The number and percentage of CGM results that can be expected to be
generated during a wear period. Sponsors should present the distribution of
the number of CGM results which were generated during each individual wear
period for all patients enrolled in the trial. This analysis should include data
from all sensors that were calibrated and able to generate data for at least one
hour. The percentages of results generated should also be calculated using the
total number of values that were possible during each wear period as the
denominator, i.e., periods of sensor failure or signal dropout should not be
subtracted from the duration of evaluation.

2.
BGD Component
Sponsors should provide appropriate safety and effectiveness information for the
Blood Glucose Device (BGD) component of the CGM, FDA recommends that
Sponsors refer to recent and applicable study guidelines, such as those published by
the Clinical and Laboratory Standards Institute (CLSI, http://www.clsi.org), and
applicable FDA guidance documents to assist with the design of the analytical and
clinical evaluation studies and the data analysis.15,16,17,18 Sponsors should identify all
applicable standards or FDA guidance documents they followed as they evaluated the
device. Because the accuracy of the BGD exerts a tremendous impact on the quality
of the calibration and the performance of the APDS Sponsors are encouraged to
consider use of the most accurate BGD devices that are practical for patient use.
15

CLSI EP5-A2 Protocol (Evaluation of Precision Performance of Quantitative Measurement Methods;
Approved Guideline—Second Edition).
16
CLSI EP7-A2 Protocol (Interference Testing in Clinical Chemistry; Approved Guideline- Second Edition).
17
CLSI EP6-A document (Evaluation of the Linearity of Quantitative Measurement Procedures, A Statistical
Approach; Approved Guideline, 2003).
18
CLSI EP9-A3 protocol (Method Comparison and Bias Estimation Using Patient Samples; Approved
Guideline- Third Edition).
23

Contains Nonbinding Recommendations

The performance specifications of the BGD and the study protocols and data
generated to verify them, including, for example:
· Bias
· Imprecision
· Linearity
· Measuring range
· Traceability to reference materials or methods
· Stability of device components
· Expected values, as appropriate
· Detection limit (e.g., limit of blank, limit of detection, and limit of
quantification), as appropriate
· Analytical specificity, as appropriate, including:
o Cross-reactivity with compounds that have similar molecular structures,
such as maltose;
o Interference from endogenous compounds such as ascorbic acid;
exogenous compounds such as prescription and over-the-counter
medications; or medical conditions such as ketoacidosis or abnormal
hematocrit concentrations; and
o Environmental interference (e.g., from temperature, humidity and
altitude).
· User studies (where intended users collect (e.g., performing the fingerstick)
and analyze the sample, and where results from the BGD are compared to
results obtained with a traceable reference method.)
· Matrix comparison, if more than one sample type may be analyzed.
· Lot release criteria used during the manufacturing of the BGD reagent or test
strips.
Study protocols should minimally include, as applicable: number of patients, number
of samples tested, matrix and concentration of the sample tested, number of replicates
tested, number of meters, number of test strip lots and the statistical analysis used.
The BGD is an essential part of the APDS. Like the other essential parts of the APDS
(e.g., the CGM and the insulin pump), it is a part of the APDS device and will be
regulated as a part of a class III device. As such all information sufficient for
approval of the BGD as part of the system should be provided in the PMA submission
(e.g., manufacturing information, specifications, etc.). If, as indicated in Section IV
above, the BGD is an FDA approved device and the device has not been modified
then a reference to the approval and product labeling may be sufficient.19
19

Because the intended use of an APDS is different than the intended use of a continuous glucose monitor
(CGM), FDA believes additional information will be needed for blood glucose devices (BGD) that are part of an
APDS compared to the information required for a BGD that is part of a CGM. The Agency does not intend to
request this information for one year following the publication of this notice for the BGD component of APDS
submissions. One year after issuance of this notice, PMAs for APDS should include complete information (e.g.,
manufacturing, specifications, etc.) for the BGD component of the APDS.
24

Contains Nonbinding Recommendations

K .APDS Control Algorithm/Signal Processing
Functional Component
The complete description of the APDS control algorithm should be provided as discussed
in Section IV.C above. In general, Sponsors should submit the APDS control algorithm
for an APDS for review as part of the PMA, consistent with FDA practice for other
devices that use similarly complex algorithms. In addition to the description, there are
critical elements of the APDS control algorithm that support its safe use that Sponsors
should provide:
·

APDS Control Algorithm Verification – prior to clinical use, the sponsor should
test the APDS control algorithm to assure that it has been properly programmed
into software and provide verification. Details surrounding this verification testing
can be found in Appendix A Section V.C. In addition, FDA recommends that
Sponsors describe how they have assured the correct APDS control algorithm has
been properly coded into their final finished device as part of their PMA
applications.

·

Parameter Sensitivity Analysis - the APDS control algorithm in an APDS may
contain parameters that are adjustable by the healthcare provider or patient. These
adjustable parameters should be identified in the device description. Although a
limited sensitivity analysis is expected prior to an IDE approval (Appendix A,
Section V.A.5), Sponsors should provide a comprehensive parameter sensitivity
analysis as part of their PMA applications. This analysis should evaluate the
likelihood of an improper/unsafe insulin dose or insulin pump shutoff for all
combinations of adjustable parameter values using representative CGM tracings.
The CGM tracings should be representative tracings of the selected patient
population.

If using theoretical or computer modeling to test the APDS control algorithm, the
Sponsor should provide tracings that demonstrate device behavior when values
outside the bounds of expected use are encountered so as to describe device behavior
under worst-case scenarios. A summary of the complete test report, justification of
how the CGM tracings used are representative of the intended patient population, and
reference to the full test report in the software documentation set should be provided
by the Sponsor.

L. Infusion Pump Functional Component
FDA recommends Sponsors provide appropriate information regarding the safety of the
infusion pump, including the following information:
Drug Stability and Compatibility

25

Contains Nonbinding Recommendations
The Sponsor should demonstrate that the system does not adversely affect the drug
product being delivered by the infusion pump and that these products do not adversely
affect the infusion pump.
If the infusion pump includes a reservoir or container, the Sponsor should provide
stability and compatibility data, which assesses the stability and compatibility for the
recommended use period and conditions included in the drug product labeling. The
assessment should include an assay to demonstrate that the drug retains its specifications.
The Sponsor should also provide a safety evaluation of any extractables, leachables,
impurities and degradants.
The sponsor should demonstrate that drug formulation does not adversely affect
performance of other components, namely the CGM. For example, some insulin
formulations may contain preservatives or stabilizers that may interfere with CGM
performance via electrochemical reaction.
Some infusion pumps use syringes as the "drug reservoir" to contain the product that is
being infused. If the infusion pump is set up in this configuration, the Sponsor should
adapt the stability and compatibility testing stated in the paragraph above to include
combinations of drugs and syringes that are intended to be used with the pump functional
component.
The Sponsor should verify that the mechanical structure and function of any drug
contacting components are not degraded to the point that harm could occur to the patient
or infusion pump user.
As noted in Section VIII-Labeling, the Sponsor should identify the particular drugs that
have been evaluated for use with the infusion pump functional component. For pumps
that utilize a syringe as the "drug reservoir," the labeling should identify the specific
syringes that are approved for use with the pump.
Catheter Occlusion Bench Testing
If the APDS is designed to completely turn off insulin delivery, Sponsors should provide
a complete test report in the PMA submission describing the bench testing performed to
show catheter occlusion does not occur when the pump is turned off. Details of the
Catheter Occlusion Bench Testing can be found in Appendix A, Section V.J, along with a
discussion of what needs to be provided in an IDE.
Dose Accuracy
Sponsors should provide a complete test report in the PMA submission describing the
dose accuracy of the pump. The testing should focus on the ability of the pump to
accurately deliver the recommended dose of the APDS control algorithm. The purpose of
this testing is to understand how well the infusion pump can deliver the wide range of
recommended doses. Details of the Dose Accuracy Bench Testing can be found in
Appendix A, SectionV.L, along with a discussion of what needs to be provided in an IDE.

26

Contains Nonbinding Recommendations

V II.Clinical Study Progression
The guidelines in this section are intended to facilitate timely progression from an early
feasibility study to a full pivotal investigation while assuring adequate patient protections. In
developing these recommendations, we have considered the least burdensome approach.
Each step is designed to test specific aspects of the APDS functionality and performance.
We recognize that not all APDS systems will need to go through all of the study stages.
Sponsors who believe they already have sufficient, valid scientific evidence to fulfill the
purpose of a particular study phase and justify moving to the next study phase are encouraged
to present and discuss the evidence with FDA staff. Such evidence may be clinical or nonclinical and may be obtained from studies performed outside the US that comply with 21
CFR 814.15.
FDA recommends that the APDS be studied in two general phases: feasibility and pivotal
studies. Feasibility studies can be either exploratory in nature as part of device development
and/or intended to demonstrate that the APDS functions as expected and has no obvious,
unexpected safety concerns in either the in-patient or outpatient setting. Pivotal studies
should be performed with a final device system and the study should evaluate the
performance of the system in the intended setting.
The size and duration of each study phase is dependent on the purpose of the study being
performed, the design and features of the APDS and its proposed indication. Each APDS
will likely have unique features that affect study design. Therefore, the guidelines below do
not set specific requirements for size and duration, but rather build in maximum flexibility
for completion of each study phase, while also aiming to take the least burdensome approach.
In addition, because some APDSs may be composed of parts that have already been approved
or cleared by FDA, in such cases, Sponsors should leverage what is already known about the
safety and effectiveness of the individual components to streamline the clinical testing and
study progression of such a system. For example, additional clinical studies may not be
needed if a Sponsor is able to demonstrate that a newly introduced component is similar to
the previously approved version, e.g., in terms of its accuracy, susceptibility to interferences,
human factors, etc. In such cases Sponsors should contact FDA with a justification
explaining why additional clinical studies are not warranted, in advance of making
substitutions.

A . Feasibility Studies
Overview and Early Stages
As noted above, feasibility studies (sometimes referred to as pilot studies) can be either
exploratory in nature as part of device development, and/or intended to demonstrate that
the device system functions as expected, does not have any obvious unexpected safety
concerns, and can address the hazards associated with errors in the individual system
components and the system as a whole. FDA expects that early feasibility studies will be

27

Contains Nonbinding Recommendations
of short duration, involving few patients. The precise number of patients will depend on
the device hazards identified and the success of the implemented mitigating factors. FDA
envisions that early feasibility studies will generally evaluate the APDS in an in-patient
setting under significant supervision of medical personnel, under controlled conditions.
Early feasibility studies would then gradually transition to later-stage feasibility studies
with progressively less supervision and would move into the out-patient setting. The
clinical protocols for the feasibility studies should be developed with identifiable goals
and pre-specified success criteria. The objectives of feasibility studies might be to:
·
·
·
·

·
·

Provide proof of a system concept, i.e., the components and an APDS control
algorithm.
Examine the effects of specific modifications to the APDS control algorithm.
Validate performance of the APDS across the operating range of the CGM.
Isolate and examine how the APDS control algorithm performs when exposed to
conditions known to challenge the system, e.g., meal challenges, exercise,
obstruction in infusion set tubing or cannula and errors in the system’s
components.
Combine stress conditions in order to more realistically capture home-use
conditions.
Pilot test the system in a closely supervised outpatient setting.

Information gleaned from each feasibility study could be used to make changes to the
system or adjust the APDS control algorithm. Such information also might serve to
validate the APDS control algorithm. Progression of feasibility studies should occur
when all known or reasonably expected hazards are demonstrated to be adequately
mitigated by the APDS.
As investigators conduct their early feasibility studies, it is not known whether the APDS
will adequately mitigate the risks to patients. For this reason, we generally recommend
that the early feasibility studies be performed in a hospital setting, such as a clinical
research center (CRC) under the close supervision of a medical team that can intervene to
prevent the occurrence of severe hypoglycemia or hyperglycemia. As more safety
information is collected and the hazards are shown to be sufficiently mitigated in early
feasibility studies, less-supervised studies can be performed (e.g., a supervised outpatient
study). These studies could be conducted in a variety of settings; for example, in a hotel,
or in a diabetes “camp” or “dormitory,” which would allow subjects to undertake more of
their day-to-day activities while being closely monitored by on-site personnel. Studies
may then progress to gradually decrease monitoring in these out-patient settings.
Sponsors conducting feasibility studies should demonstrate that their APDS can
adequately identify and compensate for CGM errors prior to moving to a less supervised
outpatient setting.
Later-Stage (Transitional) Feasibility Studies to Characterize APDS performance
over Device Use Life

28

Contains Nonbinding Recommendations
Later-stage feasibility studies, also known as transitional studies, can provide the
opportunity to gain additional feasibility information for the development of the APDS.
The later feasibility studies should include stress testing of the APDS to identify any
potential limitations that should be addressed prior to the pivotal study. When
appropriate, additional blood glucose results can be obtained. For example, these laterstage feasibility studies could be used to evaluate APDS performance over the life of its
disposable components, or to test the functionality of components in outpatient settings
by challenging the system with some supervision (for example, intense and prolonged
exercise, periods of not eating, or reducing caloric intake). These types of studies should
be conducted for a duration that assures the safe and effective continuous use of system
components such as the CGM, catheter, and reservoir. For disposable components, the
study should be conducted for a period of time that allows the Sponsor to measure device
performance before, during and after the disposable components are changed. Sensors
and pump reservoirs should be replaced as recommended.
Sponsors will ideally use the same version of the APDS in these later stage feasibility
studies that will be used in the pivotal study. If modifications to the APDS are made
between the feasibility studies and pivotal study, bridging studies may be appropriate;
however the need for, and nature of bridging studies will depend upon the type and extent
of the change(s). We recommend the Sponsor seek FDA input prior to implementing the
change(s) to any of the device components included as part of the system, between the
feasibility and pivotal studies.
In an effort to minimize any delay between feasibility study completion and pivotal study
initiation, the Sponsor may choose to submit the later-stage feasibility and pivotal study
plans for review concurrently and predefine the later-stage feasibility study success
criteria. FDA may approve the design of the pivotal study contingent upon successful
completion of the agreed upon later-stage feasibility study plan and submission of the
study results.
Feasibility-Studies to Demonstrate Performance of Risk Mitigation Strategies
Generally, feasibility studies should be designed to demonstrate that the APDS system
can adequately mitigate the risks associated with various conditions. For example,
feasibility studies should demonstrate effective mitigation measures when the insulin
pump stops functioning or when the insulin pump does not deliver the appropriate dose.
Additionally, feasibility studies should address the issue of significant errors in CGM
readings. Currently marketed CGMs experience periods when they generate incorrect
data, e.g., indicating that glucose levels are significantly above or below the true blood
glucose value, or that glucose levels are rising when they are actually falling (or falling
when they are actually rising). Incorrect information of this critical nature, if fed into the
APDS, can be life-threatening to the patient. An additional consideration is that CGMs
may stop providing data, e.g., they may fail to provide data for several hours or they
might stop functioning altogether. This latter condition might also have serious

29

Contains Nonbinding Recommendations
consequences, especially if the patient were sleeping at the time and failed to respond to
an alarm.
To provide safety monitoring and for purposes of assessing the accuracy of CGM values
during the study, reference blood glucose measurements (i.e., those measured with a
traceable laboratory reference method) should be collected and checked frequently. The
reference blood glucose measurements will allow the Sponsor to detect when a CGM
error may be occurring and anticipate the severity of the error and its effect on the patient.
The Sponsor should design feasibility studies to verify that the APDS can adequately
mitigate CGM errors. The following is a current list of common types of CGM errors.
One method by which Sponsors could simulate these errors might be to manually enter
false CGM information into the APDS. The effects of these errors should be evaluated at
both low and high glucose levels as the effects and potential impacts vary at different
glucose levels.
·
·
·

·

Erroneously high CGM values.
Erroneously low CGM values.
Erroneous CGM trending information:
o CGM indicates that glucose concentrations are rising when they are actually
falling;
o CGM indicates that glucose concentrations are falling when they are actually
rising; and
o Rate of change in glucose concentrations measured by CGM is incorrect, or
biologically implausible.
The sensor stops functioning:
o For a short and intermediate length of time;
o Completely (such as what might occur when the sensor fails or when it
reaches the end of the wear period); and
o Any other hazards that occur during the early feasibility study should be
recorded as an incident for data analysis.

We recognize that, as CGM technology improves, these factors may change. We
encourage Sponsors to discuss with us any other potential errors they wish to
measure through a pre-IDE.

B. Pivotal Clinical Study
Generally, a pivotal study is performed to gather data to support the safety and
effectiveness of the device. As such, a pivotal study, or studies, should be performed in
the actual use, real-world environment and by the intended use population. A pivotal
study can be conducted with subjects in their homes going about their normal activities of
daily living or in children not only at home but also at school and participating in sports.
The pivotal study should be conducted with the finished APDS for which approval will
be sought and should be designed to demonstrate the safety and effectiveness of the

30

Contains Nonbinding Recommendations
complete device system in the intended use population. Please note that, as discussed
above, not all outpatient studies will be pivotal trials.
To demonstrate the safety and effectiveness of the APDS, we recommend comparing
outcomes between patients using sensor-augmented pump control, and patients using the
APDS. Sponsors should select a control group that uses currently available technology to
allow a comparison between the use of this technology and the addition of the algorithm
as part of the system. How the devices are used during the study should be based on the
currently accepted treatment goals for the intended use population and the Sponsor’s
intended labeling claims about the performance of the device. FDA recommends a study
duration long enough to allow for multiple periods of sensor wear and to evaluate
changes in subject needs over time. We anticipate that designs of acceptable pivotal trials
will evolve as the devices to which a comparison should be made change and as the
technologies continue to improve.
A robust trial design to validate an APDS could include a randomized cross-over design
or a randomized parallel design for evaluating the safety and effectiveness of the APDS in
an outpatient setting. Patients in the control group should manage their diabetes
according to the standard of care, e.g., by responding to alarms, performing finger stick
blood glucose tests, and determining therapy according to these results. Patients in the
test group should monitor their glycemic control by responding to alarms, performing
finger stick blood glucose tests, and adjusting their treatment according to these results as
directed by the instructions for using the APDS.
The following considerations are important for the Sponsor to take into account when
designing a pivotal study:

1.

Patient Population

The overall goal of an APDS clinical study is to provide reasonable assurance of the
safety and effectiveness of the APDS within its intended use; for example, to maintain
glucose values within range or near target while minimizing adverse events such as
hypoglycemia and hyperglycemia. Sponsors may choose their study population but
should recognize that the population they select to study may influence the study
design, sample size, duration of follow-up, and final approved device indications.
FDA recommends consideration of the following criteria for enrolling patients with
DM into initial studies for the APDS:
Initial subject population:
· Experienced with pump > 6 months.
· Willing to perform ≥ 4 finger stick blood glucose measurements daily.
· Willing to perform manufacturer-required sensor calibrations.
· Willing to wear the system ≥ 6 days per week.
· Willing to keep a minimum log of:
o sick days

31

Contains Nonbinding Recommendations
o days with exercise
o symptoms of low and high blood glucose episodes
o medications, both prescription or over the counter.
In general, FDA recommends that initial studies for a novel APDS be performed in
subjects age >18 years to ensure adequate ability of patients to respond to device
problems. FDA is very interested in promoting the development of a safe and
effective APDS for subjects < 18 years. Younger subjects should generally be
enrolled after a sufficient number of adults have been studied, and it has been shown
that the APDS system does not present a significant risk, and has the potential to
demonstrate a therapeutic benefit; thereby justifying that anticipated benefit exceeds
the risk. (21 CFR 50 Subpart D).
To improve study efficiency by reducing sample size and study duration, Sponsors
may wish to enrich the patient population with subjects more likely to reach a study
clinical endpoint. Some examples of potential populations are as follows:
·
·
·

Patients with a high % HbA1c and frequent hypoglycemia despite aggressive
attempts at improved glycemic control;
Patients who have purposely maintained a high HbA1c to avoid any
hypoglycemia;
Patients who have frequent hypoglycemia.

Comparator Population:
It is important that any study designed to examine the APDS should specifically test
the effects of the APDS functionality compared to appropriate clinical practice and
not simply the effects of the newly implemented sensor-augmented pump control.
Sponsors should choose the appropriate population to compare to based on their
indication; labeling and claims will need to reflect the study and how it was
performed. Sponsors who desire to develop their APDS for a specific patient
population are encouraged to seek FDA advice through a pre-IDE submission to
determine how they can most efficiently assess the safety and effectiveness of the
device for use in that population.
Broadening the Patient Population
Sponsors may want to widen the criteria for the enrollment of subjects (e.g., patients
who are younger, or have co-morbidities that may increase their risk during the study)
and should consider how the inclusion of different subject groups may affect the study
design, endpoints, and analysis of study outcomes. For example, if the Sponsor
chooses to pursue a pediatric-specific indication,20 the pediatric inclusion and
20

The pediatric population is defined as birth to 21 years of age. For details surrounding this definition and
recommended pediatric subpopulations, please refer to Guidance for Industry and Staff: Pediatric Expertise for
Advisory Panels
(http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm0821
32

Contains Nonbinding Recommendations
exclusion criteria should be identified, as should any protocol-specific issues (such as
exercise or the daily volume allowed for blood draws, etc.). However, criteria in
21CFR 50 Subpart D must be met.

2.

Study Endpoints

Clinical study endpoints should represent objective characteristics or variables that
reflect how a patient feels, functions, or survives. Surrogate endpoints should predict
meaningful clinical outcomes and be based on valid scientific evidence. Endpoint
assessments may, for example, be based on blood glucose concentration, imputed
from CGM-based values, and/or clinical symptoms, as appropriate for the study.
Use of CGM Data
Most endpoints that will be used to evaluate APDS performance call for measurement
or estimation of blood glucose levels. The characteristics of an APDS necessitate
frequent and long-term measurement of blood glucose, and designing a study to
achieve this can be challenging. The American Diabetes Association (ADA)
Workgroup on Hypoglycemia acknowledged the limitations for obtaining plasma
glucose values noting that “although a precise laboratory-based plasma glucose
measurement would be ideal, monitor-based estimates (or those with a validated
glucose sensor) are the only practical method.”21
FDA held a joint workshop in collaboration with the National Institutes of Health,22
which discussed the clinical expectations of clinical studies for artificial pancreas
device systems. As a result of this workshop and continued collaboration, FDA finds
that use of CGM data in evaluating the APDS is appropriate and acceptable.
Endpoints
Several endpoints can be utilized by Sponsors based on their particular device and
how it addresses patients’ needs. The endpoints for the APDS should show safety
and effectiveness and reflect the anticipated device indications for use. Co-primary
endpoints may be acceptable and could be used by a Sponsor to support a PMA. Other
effectiveness endpoints may also be considered based on the intended use of the
device. We encourage Sponsors to select their study endpoints considering the
indications for use of their device and intended marketing claims. We encourage
sponsors to discuss their proposed endpoints and study designs with FDA; particularly
prior to beginning any pivotal studies. Several potential endpoints are noted below,
but Sponsors should recognize that this is not an exhaustive list.

88.pdf). For the purposes of the LGS system, FDA recommends the subpopulation of 18-21 be considered
transitional adolescents enabling this pediatric subpopulation to be studied with adults
21
American Diabetes Association Workgroup on Hypoglycemia. Defining and Reporting Hypoglycemia in
Diabetes (2005), Diabetes Care 28: 1245-1249.
22

November 10, 2010, Innovations in Technology for the Treatment of Diabetes: Clinical Development of the
Artificial Pancreas (and Autonomous System).
33

Contains Nonbinding Recommendations
Hypoglycemia/Hyperglycemia - The following are examples of methods of
evaluating or imputing hypoglycemia or hyperglycemia as part of a study:
· Number of hypoglycemic and hyperglycemic events (biochemical, clinical,
or both) or event rate; where an event is defined a priori by the sponsor.
· Time spent (hours/week) in hypoglycemia or low glycemic concentrations
(e.g., sensor values <70 mg/dL) and hyperglycemic or high glycemic
concentration events (e.g. sensor values > 240 mg/dL), including both day
and night.
· Average duration for all hypoglycemic or low glycemic concentration
events (e.g. sensor values <70 mg/dL) and hyperglycemic or high glycemic
concentration events (e.g. sensor values > 240 mg/dL), within each group.
· Mean area under the curve (AUC) for all hypoglycemic events <70 mg/dL
and hyperglycemic events > 240 mg/dL.
HbA1c - HbA1c estimates the average glycemic exposure of red blood cells over a
90-day period. It is the primary efficacy measure used in the majority of trials
assessing the effectiveness of a treatment or intervention on glycemic control.
Additionally, HbA1c has been used to inform our understanding of the association
of long-term glycemia and the development of complications associated with
diabetes. While HbA1c can be used as a primary endpoint in the support of a
premarket application, it could also be used during post market studies to
demonstrate no increase in % HbA1c.23 We note that Sponsors may propose that
in certain populations, acceptable increases in % HbA1c may be offset by benefit
in another endpoint (such as a reduction in hypoglycemic events).
Time In Range – Time in Range (TIR) is an endpoint that measures how
successfully an APDS is able to keep glucose within a pre-defined range. When
evaluating TIR, it is important to also assess the effect of the device on clinical
symptoms, to assess glucose values above and below the desired ranges, and to
understand its relationship to other markers of glycemic control.
Safety - A safety study of an APDS should determine that the APDS does not
increase the incidence of severe hypoglycemia (e.g., seizure or need for third party
assistance), severe hyperglycemia or diabetic ketoacidosis (DKA). In designing
the safety study, the Sponsor should propose specific safety endpoints that address
these concerns. Some examples of the types of endpoints Sponsors may consider
in developing a safety study include the following metrics, which the APDS
should be shown not to increase to a clinically significant degree:
· Severe hyperglycemia and elevated ketones;
23

There is significant variability in performance among HbA1c assays and point-of-care HbA1c test systems
many not be as accurate as assays performed in central laboratories. Therefore, Sponsors should minimize
potential variables in the study by having all study subjects’HbA1c values determined at one central laboratory
location using only a National Glycohemoglobin Standardization Program (NGSP) certified method. The
Sponsor should provide the name of the HbA1c test system that was used to obtain the HbA1c values and
indicate whether it is a NGSP certified method.
34

Contains Nonbinding Recommendations
·

DKA (please refer to the Appendix A, Section H for a discussion of ketone
risk);
· Number of CGM-defined hyperglycemic events;
· Mean area under the curve (AUC) above 240 mg/dL as calculated from
CGM readings;
· HbA1C above a predefined accepted increase that may occur as a result of
reduction of hypoglycemia or from inappropriate pump suspensions or
decreased insulin delivery;
· Percentage of CGM readings in the higher hyperglycemic ranges;
· Severe hypoglycemia (e.g., seizure or need for third party assistance);
· Number of CGM-defined hypoglycemic events;
· Mean AUC below 60 or 70 mg/dL as calculated from CGM readings; or
· Percentage of CGM readings in the hypoglycemic range (< 60 or 70
mg/dL).
There are various other safety endpoints that could be used depending on the
intended use of the device.
Other Endpoints- Additional potential endpoints, as appropriate for the intended
use of the device (whether as primary or secondary), include, but are not limited
to:
· Incidence of catheter blockage within each group.
· Capillary blood glucose values above and below the Sponsor defined hypo
and hyperglycemia thresholds (e.g. < 70 mg/dL and > 240 mg/dL).
· Fasting whole blood ketone concentrations within each group, evaluating
elevated beta-hydroxybutyrate concentrations.
· Glycemic variability (such as coefficient of variation and standard of
deviation within each group).
· Incidence, severity, and timing of CGM-events for hypoglycemia and
hyperglycemia (e.g., timing during the day and night).
· Safety and efficacy sub-group analysis, such as for pediatric subjects.
· Quality of Life.
· Weighted mean AUC of CGM-events for hypoglycemia and
hyperglycemia (e.g., CGM reading between 50 and 60 mg/dL are assigned
a higher weight than those between 60 and 70 mg/dL)
Exploratory Endpoints- Other exploratory endpoints may also be considered
provided the submission identifies those endpoints as exploratory, justifies the use
of these exploratory endpoints, and proposes a clinical study that would allow
further validation of these endpoint(s).

3.

Statistical Analysis

The following discussion of statistical analyses is for studies that are intended to
support a PMA.
35

Contains Nonbinding Recommendations

Study Populations
The safety population should include all randomized subjects. For effectiveness
endpoints, two widely used populations are the Intention to Treat (ITT) Population
and the Per Protocol (PP) Population. The Intention to Treat (ITT) population should
include all randomized subjects. The Per Protocol (PP) population should include all
randomized subjects who complete the treatment period without major protocol
deviations. The ITT population is preferred for the analysis of primary endpoints.
FDA recommends the Sponsor provide details on defining the major protocol
deviation in the PP population.
Primary Hypothesis
The Sponsor should clearly state the hypothesis for each primary endpoint and define
the overall success criterion of the study.
Superiority vs. Non-Inferiority
The statistical plan for the pivotal trial should be defined in advance and may be
designed to assess either non-inferiority or superiority between the APDS and control
group endpoints.24 Sponsors should propose their non-infirmity margins prior to
beginning their studies and justify these margins. Sponsors may choose to pursue a
superiority study to justify specific APDS labeled indications and claims (such as
superiority over other approaches to insulin delivery) for endpoints other than safety
endpoints. A sponsor wishing to claim superiority for their premarket application
should determine the appropriate superiority margins and justify these margins.
Sample Size Considerations
For a cross-over or parallel study design, sample size estimates should be calculated.
FDA recommends the overall significance level be two-sided 5% and the overall
power be no less than 80%. The Sponsor should make reasonable assumptions of
important parameters, including the means and standard deviations of the primary
endpoints, the correlation between groups and within subjects, the loss-to-follow-up
(LTFU) rate, and provide justifications for these assumptions. Both the sample size
calculation and the eventual analysis should take into account the correlation of
repeated measurements made on individual subjects. For example, for analysis,
bootstrapping can be used to obtain confidence intervals. For sample size
determination, a rough method to account for dependence of repeated measurements
is to consider the “effective” sample size. Using previous data, the effective sample
size can be defined as the actual sample size times the variance when repeated
measurements are assumed independent divided by the variance obtained by
bootstrap. This definition is reasonable in the sense that variance is approximately
24

A benefit-risk analysis of the entire data set will be performed by the FDA according to: Guidance for
Industry and Food and Drug Administration Staff: Factors to Consider When Making Benefit-Risk
Determinations in Medical Device Premarket Approval and De Novo Classifications,
(http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM267
829.htm).
36

Contains Nonbinding Recommendations
proportional to sample size. An appropriate statistical method should be provided to
calculate the overall sample size while controlling the overall type I error rate under
5% and maintaining the overall power above 80%. If necessary, simulation might be
needed to calculate the sample size.
If an interim analysis is planned, the sample size should be further adjusted using
appropriate methods to control the overall type I error.
Handling of Missing Data
Starting at the study design stage and throughout the clinical trial, every effort should
be made to minimize patient withdrawals and loss to follow-ups. Premature
discontinuation should be summarized by reason for discontinuation and treatment
group. For an ITT population, an appropriate imputation method should be specified
to impute missing HbA1c and other primary endpoints in the primary analysis. It is
recommended that the Sponsor plan a sensitivity analysis in the protocol to evaluate
the impact of missing data using different methods, which may include but is not
limited to per protocol, Last Observation Carry Forward (LOCF), multiple
imputation, all missing as failures or success, worst case scenario, best case scenario,
tipping point, etc.
General Considerations for Data Analysis
FDA recommends that patient demographics, medical history, and other important
baseline characteristics (e.g., HbA1c, body mass index, average daily insulin
requirements, education levels, etc.) are summarized using descriptive statistics and
frequency tables as appropriate. Patient accountability and withdrawals from the
treatment phase of the study should be reported. Summaries (number and percent) of
the reasons for withdrawals should be presented by treatment group. The effects of
carryover, sequence, site, baseline variables and prognostic variables should be tested
using appropriate models (usually, a linear model for a continuous variable and a
logistic regression for a binomial variable).
Analysis of Primary Endpoints
The primary effectiveness analysis is the between-group comparison of all primary
endpoints. Appropriate statistical models should be specified to evaluate the impact of
covariates. If some covariates are found to confound a primary endpoint, their effects
should be adjusted through appropriate models.
Analysis of Secondary Endpoints
For all secondary endpoints, descriptive statistics are recommended. If the Sponsor
intends to make claims for any of the endpoints in the labeling then the hypotheses,
statistical analysis, and success criteria should be clearly specified in advance in the
study protocol. An appropriate multiplicity adjustment strategy to control the type I
error rate should be used.
Adaptive Study Design

37

Contains Nonbinding Recommendations
Adaptive study design provides flexibility in modifying some aspects of the clinical
study during the clinical trial. If an adaptive study design is desired, FDA
recommends that the Sponsor pre-specify details such as the number of interim
analyses, the time at which these analyses will be performed, the stopping rules, and
the criteria to control the type I error, etc. Due to the complexities of an adaptive
study design, FDA recommends the Sponsor include their proposal in their pre-IDE
submission to discuss their design.
Safety Analyses
For both investigational studies and premarket submissions, descriptive statistics of
all adverse events should be presented for the safety population. The descriptive
statistics of the following subgroups should also be summarized. This includes, but is
not limited to, the following information:
·
·
·
·
·
·
·
·

V III.

All adverse events;
Serious Adverse Events (SAE);
Adverse events and other reasons that lead to patient withdrawal from the
trial;
Unanticipated Adverse Device Effects (UADE);
Severe Hypoglycemia (prospectively defined in the protocol);
Severe Hyperglycemia (prospectively defined in the protocol);
Diabetic Ketoacidosis and hyperosmolar hyperglycemic state (prospectively
defined in the protocol); and
Skin infection.

Labeling

The premarket application must include labeling in sufficient detail to satisfy the requirement
of 21 CFR 814.20(b)(10), which states that copies of all proposed labeling for a device must
be submitted in a PMA. Labeling must also satisfy the requirements of 21 CFR Parts 801 &
809.
In general, labeling for the APDS should include:
·
·
·
·

·

A user manual for the patient, written at an 8th grade reading level;
All training materials;
Professional labeling for the prescribing physician;
Package inserts for the APDS and all components packaged separately from the
system (e.g., BGD reagents or test strips, quality control materials, catheters, inserters,
reservoirs, etc.); and
Box and container labels for the APDS and each component that is packaged
separately from the system.

38

Contains Nonbinding Recommendations
Sponsors may refer to the following documents for information on important principles for
developing clear and complete labeling for the CTR/CTT system:
·

·
·

·

Guidance on Medical Device Patient Labeling; Final Guidance for Industry and FDA
(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocu
ments/ucm070782.htm).
Labeling of Home-Use In Vitro Testing Products; Approved Guideline, CLSI GP-14
(1996).
Device Advice website titled Labeling Requirements - In Vitro Diagnostic Devices
(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/Devi
ceLabeling/InVitroDiagnosticDeviceLabelingRequirements/default.htm#).
IEC 60601-1-11 General Requirements for the basic safety and essential performance
- Collateral standard: Requirements for medical electrical equipment and medical
electrical systems used in the home healthcare environment.

The patient instructions for use should be as simple and concise as possible and be easy to
understand. Labeling for lay users should be written at an 8th grade reading level. Sponsors
should consider the use of graphics such as line drawings, illustrations, photographs, tables
and graphs. Sponsors should ensure that terms are used consistently throughout the labeling
and should avoid using synonyms or alternate phrases. Comprehensive directions for
preparation and use of all functions of the APDS and the accessories should be provided. The
Sponsor should provide labeling that contains examples of expected performance and
addresses issues that may occur in the home environment.25
The professional labeling for the prescribing physician should describe in sufficient detail the
clinical testing performed for APDS approval. The purpose of this information is to allow the
physician to make an informed decision on whether to prescribe the APDS to a particular
patient. Information such as indications, warnings, precautions, contraindications should be
provided. In addition, critical bench testing for the infusion pump (e.g., MR testing and drug
stability testing) and CGM (e.g., analytical specificity, accuracy, etc.) should be described.

IX . Manufacturing
FDA considers all of the parts of the APDS as part of the device. Sponsors should include the
information on all of the individual parts in the PMA. Once assembled, the APDS
manufacturer is responsible for ensuring the entire system is properly manufactured. Medical
device premarket applications submitted under section 515(c)(1)(C) of the Federal Food,
Drug, and Cosmetic Act (the Act) [21 U.S.C. 360(e)(c)(1)(C)], are required to include a
number of information components, as set forth in 21 Code of Federal Regulations (CFR)
Sec. 814.20. One component covers the current good manufacturing practice requirements
included in the Quality System (QS) regulation. A Premarket Approval Application (PMA) is
required to include a complete description of the methods, facilities, and controls, in
25

American Diabetes Association Workgroup on Hypoglycemia. Defining and Reporting Hypoglycemia in
Diabetes (2005),
39

Contains Nonbinding Recommendations
sufficient detail so that FDA can make a knowledgeable assessment of the quality control
used in producing the medical device (21 U.S.C. 515(c)(1)(C)). Please refer to the
appropriate guidance for more information about the quality system information needed for a
PMA.26

X . Post-Approval Study
As a condition of PMA approval, FDA anticipates that most APDSs will require a postapproval study (PAS) to better assess long-term and real-world performance and/or patient
outcomes. It is recommended that the Applicant develop a PAS protocol and submit the
protocol with the original PMA. FDA is willing to consider different PAS study designs,
depending on the APDS and its capabilities. We recommend the Applicant develop a PAS
and submit this study for review as a pre-IDE submission.

26

FDA has issued guidance on quality system information for Premarket Application Reviews, Quality System
Information for Certain Premarket Application Reviews; Guidance for Industry and FDA Staff
(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm259748.htm)..
40

A ppendix A -ID E C ontentforA PD S Studies
This Appendix provides suggested content for IDE submissions for evaluation of an APDS.
This Appendix is structured as an outline of the IDE submission and identifies the elements
of an IDE review. FDA recommends that Sponsors follow this outline and address each
section heading as part of their IDE submission. When different information is needed
between early feasibility, later-stage feasibility (transitional), or pivotal (unsupervised
outpatient setting) Studies, the section is divided.

I.

Background

The Sponsor should provide background information related to the development of the APDS
that it intends to study. The Sponsor should identify whether there has been previous
communication with FDA regarding this device within a pre-IDE submission (the Sponsor
should identify the pre-IDE #) or previous US or Outside the US clinical studies performed
using this device system (the Sponsor should identify the IDE #).

II. D evice D escription
This section should include a device description of the APDS.
If the Sponsor is using previously approved/cleared devices, the following information should
be included for each device:
·
·
·

The name of the device.
The model number.
The PMA or 510(k) number for the referenced devices.

The Sponsor should identify if the functional component has been modified from its
approved/cleared form. If so, the Sponsor should describe how the device has been modified.
This would include, for example, whether the run-in time or calibration frequency has been
modified. For all components that have been modified, Sponsors should provide a rationale
for the change and an analysis of the likely impact it will have on the performance.
If the Sponsor is not using previously approved/cleared devices, FDA recommends the
Sponsor include a complete description of all functional components of the system (i.e.,
BGD, CGM, APDS control algorithm, and pump) as described in Section IV of the guidance.
The Sponsor should also identify the insulins and/or other drugs(either as part of the system
or used concurrently with the system) that are intended to be used with the APDS in the
clinical study.

41

III. Letters ofA uthorization
Letters of Authorization (LOA) are needed if the Sponsor intends to reference
safety/effectiveness information from another manufacturer that has been included with a
device Master File27 or another regulatory submission. Some examples are identified below.
·

·

If the Sponsor intends to use a medical device from a different manufacturer that has
been modified and there is a document such as a device master file describing the
changes and additional testing for this modification.
If the Sponsor intends to use a device from a different manufacturer contained within
a document such as a device master file that allows the interconnection of various
device components into one system.

IV . Indication for U se
Describe the indication for use. Please refer to Section V of the guidance.

V . N onclinicalstudies/Prior Investigations
Per 812.27, a report of prior investigations shall include reports of all prior clinical, animal,
and laboratory testing of the device and shall be comprehensive and adequate to justify the
proposed investigation.
FDA recommends the Sponsor also provide the following information as part of the IDE.

A . APDS Control Algorithm
The Sponsor should provide information regarding the regulatory status of the algorithm
to be used in the IDE study. If the device in question utilizes software that has not been
previously reviewed and cleared or approved by FDA, a description of the algorithm
should be provided as part of the IDE submission. If the algorithm is identical to that
used in a cleared or approved product, then the IDE submission should contain the name
of the product and the FDA document number under which it was cleared or approved (if
known).
If the Sponsor does not have access to the algorithm and cannot provide it, a rationale for
why it is not being provided should be included as part of the IDE.
1. Definition of Algorithm(s)
FDA recommends the Sponsor define the algorithm in symbolic form and briefly
define the purpose for each equation in the APDS control algorithm.
2. Definition of Algorithm Symbols/Parameters
27

See 21 CFR 814.20(c). Device Advice website
(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubm
issions/PremarketApprovalPMA/ucm142714.htm).

42

FDA recommends the Sponsor define each symbol (i.e., parameter) in the algorithm.
This can be in table format.
3. Identification of Fixed Parameters
FDA recommends the Sponsor identify each fixed parameter and the value of this
parameter. FDA defines a fixed parameter as a parameter value that will not be
changed during the course of the clinical study. This can be provided in a table
format.
Symbol/Parameter

Value

4. Identification of Adjustable Parameters that May be Modified During the
Study
The Sponsor should identify each parameter and parameter value range that may be
adjusted during the course of the study. This can be provided in table format.

Parameter

Adjustable parameters
Typical
Minimum
Symbol
Starting
Value
Value

Maximum
Value

Please note, that once approval of the IDE is obtained, if the Sponsor modifies the
adjustable parameter within the predefined ranged, the Sponsor can continue the study
without notifying FDA.
5. Parameter Sensitivity Analysis
For each parameter that is defined as adjustable, the Sponsor should provide a
parameter sensitivity analysis to show the equation does not result in unsafe dosing
adjustments. For a PMA, FDA recommends the Sponsor evaluate combinations
across the entire range of parameter values and the effects on the system as described
in Section VI.K of the guidance. Such an analysis should evaluate combinations of
adjustable parameters using the minimum, maximum and typical starting value for
each adjustable parameter. The analysis should identify if any unsafe dosing
adjustments have occurred. This type of analysis can be evaluated using CGM glucose
tracings that would approximate the expected tracings observed in the study.
For early feasibility studies (Section VII.A of the guidance) where patient safety has
been significantly mitigated due to physician monitoring, a limited sensitivity analysis
is acceptable.
6. Summary of the Verification Activities for the APDS Control Algorithm
The Sponsor should provide a summary of the testing (i.e., verification activities) they
have performed to show that the APDS control algorithm has been properly

43

programmed into the software to support the safe and effective use of the device in
any IDE for a pivotal study. This summary should identify the test method used to
verify the algorithm and reference where the detailed test reports can be found in the
software documentation set.

B. Software Documentation
Software documentation should be provided for the APDS prior to major clinical studies.
Full software documentation is not necessary for early feasibility studies. However,
documentation should be provided to demonstrate that the Sponsor can trace the
development history of all components of their software and identify any unresolved
anomalies (i.e., “bugs”) that may affect the safety of their software for the purpose of
providing complete software documentation at a later time. For devices that have been
modified from their previously approved/cleared form, the Sponsor should highlight any
differences between the modified and approved/cleared versions. For assistance in
developing the appropriate documentation set, Sponsors should refer to the FDA’s 2005
software guidance document.28 All APDSs are identified as a major level of concern for
purposes of the guidance. The software documentation set can be included as an
Appendix to the IDE.
We encourage all Sponsors whose APDS is comprised of previously approved/cleared
devices that they did not manufacture to pursue obtaining an LOA from the manufacturer
of such devices to gain access to the software Master File. If the Sponsor is not able to
gain access to the software documentation in this way, the Sponsor should provide
evidence of his or her attempts to obtain the documentation and an attestation of the
manufacturers’ refusal to provide it as part of the IDE.

C . Summary of System Communication
If the APDS connects a CGM to an APDS control algorithm and/or an APDS control
algorithm to a pump in which information is passed automatically (without user
acceptance) and this is not a previously approved device system, a summary of the system
level testing is needed prior to a pivotal study. This summary should address how the
Sponsor has ensured the correct passage of information such as CGM values and or
insulin dosing recommendations. This summary should identify the test method used to
verify the APDS control algorithm and reference where the detailed test reports can be
found in the software documentation set.

D . Safety Measures for Dosing
The Sponsor should identify if there are any hard-limits coded into the software of the
APDS that would restrict the minimum and maximum dose recommended by the APDS
28

See Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices
(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm089543.htm) for
more information.

44

control algorithm. The Sponsor should identify the frequency of dosing recommendations
and the time needed to deliver the minimum and maximum dose.

E. Biocompatibility Testing
FDA recommends biocompatibility testing of the device in accordance with FDA blue
book memo, Use of International Standard ISO 10993, ‘Biological Evaluation of Medical
Devices Part 1: Evaluation and Testing’
(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocument
s/ucm080735.htm ).. The Sponsor should provide appropriate biocompatibility testing for
duration and level of contact. FDA recognizes that early studies may use device
components previously approved/cleared. If this is the case, the Sponsor should provide
the appropriate cross-reference (or an LOA) to reference the appropriate PMA or 510(k)
documents. If the Sponsor has modified the approved device, it may be possible to
reference the biocompatibility of the approved/cleared devices if the Sponsor can justify
how the modifications do not affect the biocompatibility. If the Sponsor uses a new
device, then complete biocompatibility documentation is needed as described in Section
VI.C of the guidance. FDA notes that the biocompatibility testing provided in the IDE
may be limited due to the short duration of contact of the APDS in the proposed clinical
study design.

F. Electrical Safety
If applicable, the following electrical safety information should be addressed in any IDE
submission for major clinical studies. This information may not be necessary for
feasibility studies.
Electromagnetic Compatibility
The IDE submission should include a complete description of the Electromagnetic
Compatibility (EMC) characteristics of the device, and the information to verify those
characteristics. Electromagnetic compatibility is the ability of a device to operate properly
in its intended environment of use without introducing harmful electromagnetic
disturbances into that environment.
FDA recommends that the APDS system meet the EMC requirements of IEC 60601-1-2.
IEC 60601-1-2 describes EMC testing and includes both tests for immunity of the device
to outside noise and emissions from the device to the outside. In addition to evidence of
compliance with this standard, complete testing information describing what was done,
how the device functions, modes that were tested, pass/fail criteria, reference standards,
any deviations or allowances that were taken, and any device modifications needed to
pass the testing should be provided with appropriate labeling.
Applicable Standards
The Sponsor should identify if the device meets the electrical safety requirements of IEC
60601-1, and provide complete test reports demonstrating that the device meets these
electrical safety requirements.

45

Radio Frequency
If the submission includes radio frequency (RF) technologies, the IDE submission should
include a complete description of the RF use. While applications of RF wireless
technologies might comply with applicable technology standards and Federal
Communications Commission rules, medical device safety and effectiveness concerns
may remain. Detailed information about possible hazards, can be found in the draft
guidance, Radio-Frequency Wireless Technology in Medical Devices
(http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocument
s/ucm077210.htm).29
Particular points that should be addressed in the IDE include: quality of service needed,
data integrity, coexistence, security, and EMC. Due to the increased use of RF wireless
technology that operates in the same frequency range, RF wireless coexistence via testing
with other common applications of RF wireless technology that can be expected to be in
the environment of use should be carefully addressed. The testing should also address the
ability of two or more of the systems to co-operate wirelessly in proximity.
If the Sponsor is using previously approved or cleared products, the electrical safety may
have been addressed in another regulatory submission. The Sponsor should evaluate any
differences in the test environment from the proposed clinical study and the
approved/cleared devices. Differences in test environments (e.g., home vs. hospital use)
may call for additional electrical safety testing. The Sponsor should justify these
differences are minimal or provide additional testing.

G .Animal/In-Silico Testing
The Sponsor should provide evidence of safety for the APDS intended to be studied.
FDA has accepted different types of nonclinical studies to support IDE approval. These
types are briefly described below.
Animal testing
Animal testing should employ a device system similar to that intended for use in the
clinical study. If there are any differences in the system or study timeline of the animal
study versus clinical study, these differences should be identified. The Sponsor should
justify that the differences would not affect the safe use of the device in humans. The
animal model should best represent the intended patient population, and a justification
should be provided. Prior to performing animal studies, FDA recommends that the
Sponsor seek FDA input on the animal study protocol via pre-IDE. FDA recommends
the nonclinical laboratory studies be conducted in accordance with 21 CFR 58, Good
Laboratory Practice for Nonclinical Laboratory Studies. Please note that all real-time
traces of the animal study should be provided in an appendix.

29

Note that this guidance is in draft form, but when final, this guidance will represent the Agency's thinking on
this topic.

46

In-Silico Testing
As part of the Artificial Pancreas Critical Path Initiative, FDA has accepted in-silico (i.e.,
software-based theoretical models) modeling as a reasonable nonclinical assessment tool.
An in-silico model is a method to test the APDS control algorithm in a theoretical human
model of insulin and glucose metabolism using a sophisticated computer model rather
than expensive and time-consuming animal experiments. This tool can be used to justify
and support initiation and expansion of human clinical trials. Prior to using an in-silico
model, FDA recommends submission of the model for FDA review under a pre-IDE.
This model should minimally include the variability in human glucose metabolism,
performance characteristics of the CGM and insulin pump, the pharmacokinetics of
insulin, and diffusion of glucose between the blood and interstitial fluid. A complete test
report for the in-silico testing of the APDS control algorithm should be included in the
IDE submission. Due to the flexibility of a theoretical model, the Sponsor should design
the in-silico model similar to the proposed clinical study. All real-time traces should be
provided in an appendix in the IDE.

H .Human Studies
FDA recommends the Sponsor provide all reasonably known clinical data applicable to
the safe use of the APDS in humans. This may be clinical data to support device
components of the system (e.g., CGM clinical studies), studies conducted previously in
another IDE or studies conducted outside the US. FDA recommends a complete test
report be provided.

I. Human Factors/Usability Testing
Early Feasibility Study
The early feasibility study will typically involve proof of concept for the technology; thus,
user interaction with the device will not be the focus of the study. Human
Factors/Usability Testing are generally not expected to be part of the early feasibility
study. Use errors should be collected and described in the case report forms.
Later Stage Feasibility (Transitional) Study
Risks associated with use error are present for any operator of an APDS. FDA
recommends the Sponsor evaluate the design of the system, including its labeling and
user training, during the transitional study phase to establish that the design of the system
supports safe and effective use by the intended users under conditions of simulated use
prior to the initiation of an unsupervised outpatient clinical study. Alternately, Sponsors
should design parallel human factors evaluations to assure that human error is controlled
and use-related risks are mitigated as much as possible prior to the pivotal study.
Sponsors should record all applicable human factors test protocols and results in the Case
Report Forms.
Pivotal Study

47

In an unsupervised outpatient study, data collection is limited. Self-report data (e.g., as
recorded in patient diaries) and calls to telephone help lines can provide useful
information; however these types of data should be supplemented with essential user
performance data, for example collected through a data logger incorporated into the
devices used in the study. Depending on the results obtained and consequent design
modifications implemented following analysis of results of the evaluation, it might be
necessary to perform a simulated-use test to assess the effectiveness of the modifications
and overall use safety of the system. Soliciting comments from the participants would
provide essential additional information regarding users’ perceptions of the system,
potential use-related problems, and ways in which the system might be improved.
An overview of human factors/usability testing processes is described in Section VI.I of
this document. FDA recommends the Sponsor conduct, describe, and provide a rationale
for the human factors/usability testing they conducted to support the safe use of the
system in humans in the outpatient setting.

J. Catheter Occlusion Bench Testing
APDSs are in part intended to improve glycemic control by modulating insulin infusion,
including, in certain instances, shutting the pump off for finite periods of time. Insulin
crystallization is a chemical process that occurs with or without flow, but the likelihood
of crystallization is increased in the absence of flow. Such crystallization raises the risk
of catheter blockage and the inability of the pump to deliver the appropriate insulin
dosage when the system returns insulin delivery. Although the incidence of catheter
blockage due to insulin crystallization can be further evaluated in a clinical study, FDA
recommends this risk be assessed via appropriate bench testing prior to an unsupervised
clinical study. The testing of this system should mimic the conditions of the clinical study
as closely as possible. Temperature should reflect the use environment and to ensure
safety, the duration of time evaluated should be double the maximum time allowable for
pump shutoff in the system. FDA recommends the Sponsor report the incidence of
crystallization and the incidence of catheter blockage due to crystallization.

K .Dose Accuracy Bench Testing
APDS control algorithms currently recommend periodic insulin dosing with frequencies
ranging from 1-30 minutes. These frequent bolus doses are extremely small and ask the
pump to perform accurately near the lowest doses available in the pump. In order to
understand how well the APDS can deliver the recommended insulin or drug, bolus dose
accuracy testing should be performed. This testing should evaluate the APDS using the
most frequent dosing rate (i.e., the shortest time between dosing adjustments) and
accuracy measurements should be tested using the minimum dose, maximum dose and
incremental doses between the min and max. The testing of this system should mimic the
conditions of the clinical study and the measurement technique should account for
evaporation of small doses during the testing. Temperature should be controlled and
reflect the use environment.

48

L. Diagnostic Devices to Be Used During the Clinical
Study
In addition to the diagnostic device components of the APDS, other diagnostic devices
are commonly used during clinical studies, (e.g., those that measure blood glucose for
purposes of evaluating the APDS, or ketones).
To ensure patient safety and the accuracy of these devices Sponsors should provide the
following information for each diagnostic device that will be used on site in the clinical
study:
·
·

·
·

·
·

·

·

Name of the device, including model numbers, as applicable.
Description of the function performed by the device during the study (e.g.,
monitoring patient glucose or ketone concentrations as a secondary endpoint in
the study or calibrating the CGM).
Regulatory status of the device (including the FDA document number, if known).
List of all device components and accessories. In addition to the instrument,
reagents and quality control materials, accessories might include standards
(calibrators), data transmitting equipment or software.
For labeling recommendations of device components that are part of the APDS,
please refer to Appendix A-XIII.
For diagnostic devices used in the clinical study that are not part of the APDS
system.
o Unless a justification can be provided, Sponsors should provide patients who
are operating any device all labeling associated with the device.
o Sponsors should determine whether it is necessary to provide clinical
investigators with the labeling of diagnostic devices used at the study site. If
Sponsors believe that this is not necessary they should:
§ Describe what functions the investigator will be performing with the
device and explain why it is not necessary to provide them with the
labeling. (For example, the operator may have extensive experience
operating the device.)
§ Certify that labeling will be available at each clinical site should it be
needed.
If the device was previously cleared or approved, Sponsors should describe any
physical or labeling modifications that were made to the device for purposes of
conducting the study. If modifications were made, Sponsors should:
o Describe the modification, provide a rationale for the change, and a
description of how the modification might affect device use/performance.
o Sponsors should also address how they will ensure that the instructions for use
properly communicate any changes in how the device is to be operated, if
applicable.
Sponsors should describe how performance of the device will be monitored to
ensure accurate results. This information should include, where applicable:
o Quality Control (QC) materials to be analyzed.
49

·

o Number and concentration of QC materials.
o Frequency and timing of analysis of the QC materials.
o Criteria for determining acceptability of QC results.
Sponsors should describe how individuals using the device during the study will
be trained to operate it.

M .Drugs Used During the Study
Sponsors should identify the name of the drugs (e.g., insulin, glucagon, etc.) intended to
be used in the APDS and provide the drug labeling. Sponsors should also indicate any
drugs, such as acetaminophen, sugars other than glucose, or artificial sweeteners that are
given to patients during the study, as they may affect CGM performance.
Sponsor should perform studies to address compatibility of indicated insulin drug
formulations with CGM performance.

V I. Bibliography
The Sponsor should provide a bibliography of all relevant publications. Copies of critical
publications needed to support the proposed study should be included as an appendix.

V II.C linicalStudy
A . Purpose/Objective(s)
The Sponsor should briefly describe the purpose/objective of the study.

B. Study Design
The Sponsor should briefly describe the study design. For example:
A nonrandomized double center study with X subjects who have Type I Diabetes will
participate in one X hour inpatient experiment. The study will compare the treatment
arm to a control arm. The arms are defined as:
· Treatment Arm
· Control Arm

C . Sample Size and Investigational Sites
The Sponsor should define the number of subjects that are intended to participate in the
study, the proportion of male to female, age range, Type of diabetes, etc. The Sponsor
should identify the investigational site(s) and include the address for each site.

50

D . Study Duration
The Sponsor should define the study duration for each subject (e.g., subject will
participate in two 24-hour experiments). The Sponsor should also define how long they
plan entire study will take to complete.

E. Inclusion Criteria
The Sponsor should provide a listing of the inclusion criteria. . The Sponsor should
discuss how this patient population is representative of the intended use population.

F. Exclusion Criteria
The Sponsor should provide a listing of the exclusion criteria. . For feasibility studies,
the Sponsor should discuss how the exclusion criteria mitigate risks to the subjects. For
pivotal studies, the Sponsor should ensure that the subject population remains
representative of the intended use population.

G .Study Timeline
The Sponsor should provide a detailed description of how the study will be performed.
For example:
Enrollment Visit:
Informed Consent is obtained from eligible subjects, etc.
Activities performed prior to CRC or Study Admission:
Sensor placement, etc.
CRC Admission:
Detailed description of the CRC timeline
Follow-Up
· Describe the criteria used to determine when a subject can safely be discharged
from the CRC.
· Describe when and how often a health care provider will follow-up with the
subject after discharge.

H .Safety Monitoring/Risk Analysis
The Sponsor should describe the Safety Monitoring that will be performed during the
study. For example:
·

Glucose Monitoring Risk - FDA recommends that performance of the APDS be
assessed, in part, by evaluating blood glucose measurements taken from the
subject while they are enrolled in the clinical study. It is therefore important to
collect the most accurate glucose information possible.
o Feasibility Study: For studies taking place in CRC settings, Sponsors should

51

use the most accurate method available for measuring subject glucose
concentrations, i.e., traceable reference methods. Reliable laboratory tests,
such as those utilizing a glucose oxidase or hexokinase method, are most
appropriate.
o Pivotal Study: The need for accurate glucose information also exists for
studies taking place in the home setting. The Sponsor should carefully
consider the BGD that they intend to use and assess the risk for measurement
error.
·

Hypoglycemic/Hyperglycemic Risk - To decrease the risk of severe hypoglycemia
and hyperglycemia, the Sponsor should construct a schedule for monitoring blood
glucose concentrations. The Sponsor should address how the interval of sampling
and method of determination may be affected by the subject’s current blood
glucose value or period of the trial, such as during hypoglycemia induction. This
information can be provided in tabular format.

Blood Glucose (mg/dL)
0-XX
XX-YY

Frequency of BG
measurement
X min
Y min

Please Note: The Sponsor should describe how they will intervene for
hypoglycemic and hyperglycemic episodes. This description should include time
and glucose concentration. The Sponsor should describe how each defined
episode will be treated.
·

Calibration of CGM risk - When an erroneous glucose value is used to calibrate a
CGM, the bias is carried through until the next opportunity to re-calibrate the
CGM. This can result in an incorrect bias that lasts until the next calibration (e.g.,
12 hours). Sponsors are encouraged to mitigate the risks posed by BGDs as much
as possible when designing studies because they are used to calibrate the CGMs
and could result in inappropriate insulin dosing.

·

Ketone Risk - This should be monitored by measuring urine ketones every
morning to screen for preceding nocturnal ketosis. Capillary blood ketone levels
(beta-hydroxybutyrate) should be evaluated fasting and any time the blood glucose
is above 300 or if the subject is experiencing nausea, abdominal pain, or vomiting.
First morning urine ketones may be positive even if the fasting blood is negative
for beta-hydroxybutyrate if transient nocturnal ketonemia occurred earlier during
the night as a result of insulin suspension, but subsequently resolved with
resumption of insulin infusion.

·

Sterilization Risk – The Sponsor should identify and describe if all of the devices
are sterilized, where appropriate. If not, the Sponsor should assess this risk.

52

·

Reuse Risk –The Sponsor should describe if components of the system can be
reused for other patients within the study. If applicable, the Sponsor should
describe if the reusable devices are patient contacting. If they are patient
contacting, the Sponsor should describe the reprocessing (cleaning, disinfection,
re-sterilization) of the reusable devices. Please note, validation may be needed to
ensure reusable devices have been adequately cleaned, disinfected and resterilized, as applicable.

·

Misuse Risk - Sponsors should provide a detailed description of how training will
take place regarding the operation of the APDS and all of the functional
components during the study. As applicable, this should include training for
clinical staff and/or the study subject. If the study is being conducted for the
purposes of supporting a marketing application, all training of staff and users
should mimic that which will take place when the system is marketed. This
includes written materials, videos and or checklists.

·

Risks of blood sample collection, contamination from sampling techniques.
Sample collection procedures in hospitals are responsible for a significant number
of errors when patients are in hospitals. This is particularly true when samples are
taken from an intravenous (IV) line, irrespective of the fluids being administered.
Ideally, the technique used to obtain the sample should limit the amount of blood
taken so as not to harm the patient. The technique should ensure mitigation of the
risk of contamination.

I. Stopping Rules
The Sponsor should describe stopping rules for the subject and study.
· The Sponsor should describe under what subject conditions the patient study
would be halted.
· The Sponsor should describe under what study conditions the entire study would
be halted. For example, if 3 subjects were consecutively stopped.

J. Endpoints
The Sponsor should define the study endpoints for safety and effectiveness.

K .Success Criteria/Goal
The Sponsor should define how the study will be determined a success.
Feasibility Studies
In feasibility studies, the success criteria can be general. FDA recommends the Sponsor
identify criteria that would allow the Sponsor to progress to the next study.
Pivotal Study

53

FDA recommends the Sponsor provide success criteria in accordance with the statistical
plan.

L. Statistical Analysis Plan
Feasibility Studies
These studies typically do not have sufficient sample size to allow for a statistical
analysis. The Sponsor should describe the analysis that will be used to determine
progression to the next phase of the study.
Pivotal Study
The Sponsor should describe the complete statistical analysis plan to support the study
objective(s).

V III.Inform ed C onsent
The Sponsor should provide a statement that all forms and informational materials to be
presented to the subject were submitted and included in the IDE application. A copy of the
informed consent and any informational or recruiting materials should be provided as an
Appendix. All Informed Consent documents must adhere to the requirements described in 21
CFR Part 50 – Protection of Human Subjects and must contain the information described in
21 CFR 50.25(a). If Sponsors choose to enroll pediatric subjects, or pursue a pediatricspecific indication they must be aware that the pediatric population represents a vulnerable
subgroup and special measures should be taken to protect the rights, safety, and welfare of
pediatric study subjects. The regulations at 21 CFR Part 50 - Subpart D
(http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=50&sho
wFR=1) . Additional Safeguards for Children in Clinical Investigations - further describe
specific requirements for pediatric study subjects. A copy of the informed assent form should
be included for the appropriate pediatric subpopulation.
FDA does not recommend that the consent process include only a "short form" written
consent (see section 50.27(b)(2)).

IX . PatientC ase R eportForm (s)
The Sponsor should provide a draft copy of the case report forms.

X.

InvestigatorA greem entForm s

If the investigators are determined prior to the IDE submission, the Sponsor should identify
the name and address of each investigator that will participate in the study. The Sponsor
should provide an Investigator Agreement Form and this form should minimally have the
information contained within 21CFR 812.43(c)(4). In addition to this form, the Sponsor
should certify that no investigator will participate in this study prior to signing the
investigator agreement form.

54

Financial disclosure of clinical investigators participating in a clinical study is a requirement
which applies to any clinical study submitted in a marketing application to the FDA.
Financial interests can be a potential source of bias in the outcome of a clinical study;
therefore, any financial arrangements must be disclosed. As per 21 CFR Part 54 – Financial
Disclosure by Clinical Investigators, Sponsors must certify the absence of certain financial
interests of clinical investigators on Financial Interest Form: Certification: Financial Interests
and Arrangements of Clinical Investigations FDA Form 3454
(http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM048304.pdf)
or disclose those financial interests on Financial Interest Forms: Disclosure: Financial
Interests and Arrangements of Clinical Investigators FDA Form 3455
(http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM048310.pdf).

X I. M onitoring Inform ation
The following is recommended for adequate monitoring information.
·
·

·
·
·
·

·

Written procedures for monitoring and the name and address of any monitor (21 CFR
812.25(e)).
Monitor will report to the Sponsor any noncompliance with the signed Investigator's
Agreement, conditions imposed by the IRB or FDA, and the requirements of the IDE.
Sponsor shall then either secure compliance, or discontinue shipments of the device to
the investigator and terminate the investigator's participation in the investigation (21
CFR 812.46(a)).
A Sponsor shall select monitors qualified by training and experience to monitor the
investigational study in accordance with FDA regulations (21 CFR 812.43(d)).
Monitor will conduct a pre-investigational visit. Monitor will ensure that the study
protocol is thoroughly understood.
A Sponsor shall immediately conduct an evaluation of any unanticipated adverse
device affects (21 CFR 812.46(b)(1)) and report the findings to the FDA.
A Sponsor who determines that an unanticipated adverse device effect presents an
unreasonable risk to subjects shall terminate all investigations or parts of
investigations presenting that risk as soon as possible. Termination shall occur not
later than 5 working days after the Sponsor makes this determination and not later
than 15 working days after the Sponsor first received notice of the effect (21 CFR
812.46(b)(2)).
A Sponsor may not resume a terminated investigation without IRB and FDA approval
(21 CFR 812.46(c)).

X II. InstitutionalR eview Board (IR B)Inform ation
The Sponsor should provide the following IRB information.
·
·
·
·

Identification of the IRB or IRBs.
Name, address and chairperson of each IRB.
Action taken by IRB, (i.e., approval).
Identification of how many IRBs have approved the investigation.

55

·

Identification of how many IRBs are currently reviewing the investigation or will
review it in the future.

X III.Labeling
FDA recommends the Sponsor provide the following product labeling information.
Feasibility Studies
Sponsors should provide labeling for the investigational APDS, including the instructions for
operating each of its functional components, as necessary. The purpose of product labeling
during an early feasibility or transitional study is to ensure that operators have adequate
instructions for safely operating a device during the study. Operators include clinical
investigators (when studies or a portion of a study are conducted in a clinical setting) or
patients (when a study or portion of the study takes place at home).
The amount of labeling necessary to ensure safe operation of the system or functional
components is dependent on the study design. For example, some studies involve having a
CGM inserted into patients prior to reporting to a clinic where the APDS will be evaluated,
and they are not expected to operate it while they are at home. In this example, it may not be
necessary to provide the patient with labeling for the CGM. It may only be necessary to
provide patients with instructions on what to do if they experienced an adverse event
involving the CGM, such as a reaction at the insertion site. However, a patient might be
expected to operate the CGM, BGD, APDS control algorithm, or pump, in which case they
should be provided with labeling which provides complete instructions for performing each
of the functions they are expected to carry out.
Sponsors should identify each operator involved in the study, and list each of the functions
they are expected to carry out.
Sponsors should provide a copy of the draft labeling that includes:
· Adequate instructions that enable each operator to safely perform all of the functions
they are expected to carry out during the study.
· A caution statement, “Caution – Investigational Device. Limited by Federal (or
United States) law to investigational use” on the APDS labeling.
· Unless a justification can be provided, Sponsors should provide patients who are
operating the device with all labeling associated with functions they are to perform
with the device.
· Sponsors should determine whether it is necessary to provide clinical investigators
with the labeling. If Sponsors believe that this is not necessary they should:
o Describe what functions the investigator will be performing with the device and
explain why it is not necessary to provide them with the labeling. (For example,
the operator may have extensive experience operating the device.)
o Certify that labeling will be available at each clinical site should it be needed.
Pivotal Study (unsupervised outpatient study)

56

The purpose of the product labeling should be to allow the subject to safely operate the
APDS. FDA recommends the Sponsor provide a complete set of product labeling (Section
VIII of the guidance). In addition, the product labeling should contain the following
statement, “Caution – Investigational Device. Limited by Federal (or United States) law to
investigational use”.
FDA recommends the instructions for use, such as user guides or any written materials that
will be provided to individuals during this study should be the same as what will be provided
with the system when it is marketed.

X IV . A nticipated C hanges
The Sponsor should describe any changes that are anticipated during the clinical study, for
example, if the Sponsor intends to modify the adjustable parameters during the study within
the predefined value range.

X V . M anufacturing
Feasibility Studies
Manufacturing information is not generally needed for early feasibility studies that use
devices that have already been approved or cleared. The Sponsor should describe the devices
used in the study and provide the appropriate PMA and/or 510(k) number for completion of
this section.
Pivotal Study
Sponsors should provide the following information to support a pivotal study design.
·
·

A description of the methods, facilities, and controls used for the manufacture,
processing, packing, and storage as required by 21 CFR 812.20(b)(3).
A description of the design control activities pursuant to 21 CFR 812.30.

57

A ppendix B:G lossary
Analytical specificity - How well an assay detects only a specific analyte (e.g., glucose) and
does not detect closely related substances.
Bias - The difference between the expectation of test results and an accepted reference value.
(CLSI EP21-A)
Blood Glucose Device (BGD) - A device which measures blood glucose concentrations.
Continuous Glucose Monitor (CGM) - A sensor placed under the patient's skin
(subcutaneously), which measures the glucose in the fluid around the cells (interstitial
fluid). A small transmitter continually sends information to a receiver, which converts
the information to an estimate of blood glucose.
APDS Control algorithm - An APDS control algorithm is software embedded in a
`computer that receives information from the CGM and performs a series of
mathematical calculations. Based on these calculations, the controller sends
instructions to alter the insulin infusion of the pump.
Enriched population - For this guidance, an enriched population is to study a patient
population that is likely to have a physiological phenomenon with an event frequency
that is sufficient to detect treatment-related differences in occurrence.
Imprecision - An uncertainty of measurement parameter, associated with the result of
measurement that characterizes the dispersion of the values that could reasonably be
attributed to the measurand (the quantity intended to be measured). It is expressed
numerically as standard deviation (SD) or coefficient of variation (CV). (POCT05)
Insulin infusion pump - A pump for delivering insulin into the subcutaneous tissue to
achieve glycemic control. The pump is composed of a pump reservoir similar to that of
an insulin cartridge, a battery-operated pump, and a computer chip that allows the user
to control the amount of insulin being delivered.
Interference - The act of hindering, obstructing, or impeding the performance of a device.
In-silico model - a method to test the APDS control algorithm in a theoretical human model
of insulin and glucose metabolism using a sophisticated computer model rather than
expensive animal experiments.
Linearity - The ability (within a given range) to provide results that are directly proportional
to the concentration (amount) of analyte in the test sample.(CLSI EP6-A)

58

Measuring Range - The range of values (in units appropriate for the analyte) over which the
acceptability criteria for the method have been met; that is where errors due to
nonlinearity, imprecision or other sources are within defined limits. (CLSI EP6-A)
Pediatric - Of or relating to the medical care of children. CDRH defines the pediatric age
range from birth to 21 years of age.

59


